Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
IDEXX Laboratories, Inc. (IDXX)
USD548.96
-15.25 (-2.70%)
US NASDAQ S&P 500
NASDAQ 100
Healthcare Medical - Diagnostics & Research
Address
One IDEXX Drive 4092
Westbrook, ME, US
Westbrook, ME, US
CEO
Jonathan J. Mazelsky
Website
idexx.com
IPO
1991-06-21
CIK 874716 ISIN US45168D1046
Also trades on
London Stock Exchange · 0J8P.L (USD)
NASDAQ Global Select · IDXX (USD)
Description
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
News Sentiment (7d)
Based on only 1 article — low confidence
- ALC vs. IDXX: Which Stock Is the Better Value Option? Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 2017-01-04 | — | Active |
| NASDAQ 100 | 1995-12-18 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD548.96
-15.25 (-2.70%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
627.0K
Beta
1.54
Float Shares
78.75M
Free Float %
98.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.36% | -8.12% | -5.17% | -13.49% | -25.18% | -21.08% | +4.79% | +9.53% | +4.22% | +512.64% | +112,860.69% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (22 ratings, all time)
Buy
Price Targets & DCF
Current price
548.96
Low
640.00
+16.6%
Consensus
747.50
+36.2%
Median
775.00
+41.2%
High
800.00
+45.7%
DCF (Unlevered)
180.12
-67.2%
DCF (Levered)
161.06
-70.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
60% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 5 | 0 |
| Hold | 5 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
640.00
+16.6%
|
| Last Quarter | 1 |
640.00
+16.6%
|
| Last Year | 17 |
759.53
+38.4%
|
| All Time | 28 |
650.82
+18.6%
|
Quality scores
Altman Z-Score
19.99
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
10 / 10
Strong MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
★ Strong MOAT
-
Revenue growth Medical - Diagnostics & Research: +7.9%+10.4% ★ Q1'26: +14.3% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+22.6% Q1'26: +16.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+19.3% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+31.7% ★ Q1'26: +31.8% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+43.6% ★ Q1'26: +46.7% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-3.1% ★ Q1'26: -1.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.73× Q1'26: 0.74× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 11 EPS Ana. |
Dec 2027 11 Rev. Ana. 11 EPS Ana. |
Dec 2028 11 Rev. Ana. 8 EPS Ana. |
Dec 2029 5 Rev. Ana. 6 EPS Ana. |
Dec 2030 5 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.22B
est: 1.15B (+5.5%)
|
1.29B
est: 1.24B (+4.0%)
|
1.38B
est: 1.34B (+2.9%)
|
1.49B
est: 1.34B (+11.0%)
|
1.60B
est: 1.60B (+0.3%)
|
1.78B
est: 1.77B (+0.4%)
|
1.97B
est: 1.95B (+0.8%)
|
2.21B
est: 2.21B (+0.2%)
|
2.41B
est: 2.40B (+0.2%)
|
2.71B
est: 2.67B (+1.5%)
|
3.22B
est: 3.19B (+0.6%)
|
3.37B
est: 3.36B (+0.3%)
|
3.66B
est: 3.78B (-3.3%)
|
3.90B
est: 3.88B (+0.5%)
|
4.30B
est: 4.29B (+0.4%)
|
4.70B
4.68B – 4.74B
+9.7% YoY
|
5.11B
5.06B – 5.17B
+8.7% YoY
|
5.58B
5.58B – 5.59B
+9.2% YoY
|
6.14B
6.08B – 6.20B
+10.0% YoY
|
6.98B
6.91B – 7.05B
+13.7% YoY
|
| EBITDA |
284.75M
est: 267.95M (+6.3%)
|
316.18M
est: 304.09M (+4.0%)
|
322.34M
est: 313.60M (+2.8%)
|
319.81M
est: 287.46M (+11.3%)
|
370.29M
est: 356.24M (+3.9%)
|
431.69M
est: 381.97M (+13.0%)
|
501.42M
est: 439.62M (+14.1%)
|
575.66M
est: 532.02M (+8.2%)
|
643.68M
est: 581.39M (+10.7%)
|
793.81M
est: 572.47M (+38.7%)
|
1.04B
est: 844.20M (+23.2%)
|
1.01B
est: 960.47M (+5.6%)
|
1.22B
est: 1.23B (-1.1%)
|
1.28B
est: 1.26B (+1.2%)
|
1.47B
est: 1.39B (+5.4%)
|
1.53B
1.52B – 1.54B
+9.7% YoY
|
1.66B
1.65B – 1.68B
+8.7% YoY
|
1.82B
1.81B – 1.82B
+9.2% YoY
|
2.00B
1.98B – 2.02B
+10.0% YoY
|
2.27B
2.25B – 2.29B
+13.7% YoY
|
| EBIT |
237.97M
est: 220.80M (+7.8%)
|
264.47M
est: 252.03M (+4.9%)
|
268.65M
est: 258.75M (+3.8%)
|
261.98M
est: 234.06M (+11.9%)
|
302.38M
est: 287.83M (+5.1%)
|
353.90M
est: 309.34M (+14.4%)
|
418.28M
est: 362.27M (+15.5%)
|
492.49M
est: 454.21M (+8.4%)
|
553.27M
est: 501.65M (+10.3%)
|
695.11M
est: 501.65M (+38.6%)
|
932.46M
est: 757.79M (+23.1%)
|
899.83M
est: 851.08M (+5.7%)
|
1.10B
est: 1.11B (-0.9%)
|
1.14B
est: 1.14B (+0.0%)
|
1.36B
est: 1.26B (+8.1%)
|
1.38B
1.38B – 1.40B
+9.7% YoY
|
1.50B
1.49B – 1.52B
+8.7% YoY
|
1.64B
1.64B – 1.64B
+9.2% YoY
|
1.81B
1.79B – 1.82B
+10.0% YoY
|
2.05B
2.03B – 2.07B
+13.7% YoY
|
| Net Income |
161.79M
est: 151.25M (+7.0%)
|
178.27M
est: 171.10M (+4.2%)
|
187.80M
est: 182.24M (+3.1%)
|
181.91M
est: 163.12M (+11.5%)
|
192.08M
est: 184.22M (+4.3%)
|
222.05M
est: 196.05M (+13.3%)
|
263.14M
est: 228.14M (+15.3%)
|
377.03M
est: 348.46M (+8.2%)
|
427.72M
est: 388.00M (+10.2%)
|
581.78M
est: 418.39M (+39.1%)
|
744.85M
est: 604.02M (+23.3%)
|
679.09M
est: 662.67M (+2.5%)
|
845.04M
est: 821.99M (+2.8%)
|
887.87M
est: 843.72M (+5.2%)
|
1.06B
est: 1.04B (+1.6%)
|
1.17B
1.16B – 1.19B
+12.1% YoY
|
1.34B
1.30B – 1.37B
+14.4% YoY
|
1.46B
1.44B – 1.59B
+9.4% YoY
|
1.74B
1.71B – 1.76B
+18.9% YoY
|
2.11B
2.08B – 2.13B
+21.1% YoY
|
| SGA |
334.24M
est: 314.84M (+6.2%)
|
354.57M
est: 340.23M (+4.2%)
|
401.35M
est: 389.88M (+2.9%)
|
457.60M
est: 403.21M (+13.5%)
|
482.47M
est: 462.50M (+4.3%)
|
524.08M
est: 465.28M (+12.6%)
|
575.17M
est: 503.71M (+14.2%)
|
632.34M
est: 583.53M (+8.4%)
|
679.51M
est: 612.61M (+10.9%)
|
735.27M
est: 548.02M (+34.2%)
|
796.40M
est: 656.57M (+21.3%)
|
850.75M
est: 838.69M (+1.4%)
|
901.89M
est: 949.80M (-5.0%)
|
1.03B
est: 973.35M (+5.9%)
|
1.05B
est: 1.08B (-2.5%)
|
1.18B
1.18B – 1.19B
+9.7% YoY
|
1.28B
1.27B – 1.30B
+8.7% YoY
|
1.40B
1.40B – 1.40B
+9.2% YoY
|
1.54B
1.52B – 1.56B
+10.0% YoY
|
1.75B
1.73B – 1.77B
+13.7% YoY
|
| EPS |
1.43
est: 1.21 (+18.2%)
|
1.62
est: 1.45 (+11.7%)
|
1.77
est: 1.65 (+7.3%)
|
1.82
est: 1.61 (+13.0%)
|
2.07
est: 2.06 (+0.7%)
|
2.47
est: 2.38 (+3.9%)
|
3.00
est: 3.15 (-4.9%)
|
4.34
est: 4.20 (+3.5%)
|
4.97
est: 4.75 (+4.5%)
|
6.82
est: 6.10 (+11.8%)
|
8.74
est: 8.38 (+4.3%)
|
8.12
est: 7.91 (+2.7%)
|
10.17
est: 10.19 (-0.2%)
|
10.77
est: 10.46 (+3.0%)
|
13.17
est: 12.93 (+1.9%)
|
14.63
14.43 – 14.76
+13.2% YoY
|
16.53
16.17 – 16.98
+13.0% YoY
|
18.71
17.90 – 19.76
+13.2% YoY
|
21.55
21.26 – 21.83
+15.2% YoY
|
26.10
25.75 – 26.44
+21.1% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-28 | UBS | Neutral | Neutral | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | B | 3/5 | 3/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.14B
OE per share TTM
14.12
Owner's Yield
2.67%
Maintenance CapEx ratio
0.35%
Maint CapEx / Avg PPE
22.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
504
Total invested
3.04B
Insider transactions (90d)
1
Beneficial owners (>5%)
18
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 8.99M | 10.60% | 7.88M | — | 8.99M | — | HC | Delaware | 2022-01-27 | ↗ |
| 2 | 13-2628641 | 8.03M | 8.82% | 8.03M | — | 8.03M | — | IA | Delaware | 2016-02-16 | ↗ |
| 3 | The Vanguard Group - 23-1945930 | 7.92M | 9.34% | — | 143.8K | 7.57M | 352.0K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 4 | Fundsmith LLP | 4.45M | 5.37% | 4.43M | — | 4.45M | — | IA | United Kingdom | 2023-02-14 | ↗ |
| 5 | 52-0556948 | 4.43M | 4.90% | — | — | — | — | IA | Maryland | 2017-02-07 | ↗ |
| 6 | Neuberger Berman Inc. | 3.99M | 6.70% | 234.7K | 3.10M | — | 3.99M | HC | Delaware | 2009-02-12 | ↗ |
| 7 | Neuberger Berman Group LLC | 3.64M | 6.17% | 232.1K | 2.81M | — | 3.64M | HC | Delaware | 2009-06-11 | ↗ |
| 8 | Brown Advisory Incorporated ("BA, Inc.") | 2.89M | 5.29% | 2.12M | — | — | — | HC | BA, Inc is a Maryland Corporation | 2013-02-07 | ↗ |
| 9 | Neuberger Berman Management LLC | 2.81M | 4.76% | — | 2.81M | — | 2.81M | BD, IA | Delaware | 2009-06-11 | ↗ |
| 10 | BLAIR WILLIAM & CO/IL | 2.80M | 5.88% | 1.78M | — | 2.80M | — | BD, IA | 222 W. Adams, Chicago, IL 60606' | 2015-07-02 | ↗ |
| 11 | Neuberger Berman Equity Funds | 2.80M | 4.74% | — | 2.80M | — | 2.80M | IV | Delaware | 2009-06-11 | ↗ |
| 12 | Brown Advisory, LLC ("BA,LLC") | 2.74M | 5.02% | 1.97M | — | — | — | IA | BA,LLC is a Maryland Company | 2013-02-07 | ↗ |
| 13 | 061523639 | 2.53M | 8.08% | 97.9K | 2.00M | — | 2.53M | HC | Delaware | 2007-02-13 | ↗ |
| 14 | 135521910 | 2.53M | 8.08% | 97.9K | 2.00M | — | 2.53M | BD, IA | Delaware | 2007-02-13 | ↗ |
| 15 | 132667528 | 2.00M | 6.40% | — | 2.00M | — | 2.00M | IA | New York | 2007-02-13 | ↗ |
| 16 | 134035886 | 1.98M | 6.33% | — | 1.98M | — | 1.98M | IV | Delaware | 2007-02-13 | ↗ |
| 17 | Brown Investment Advisory & Trust Company ("BIATC") | 149.4K | 0.27% | 145.6K | — | — | — | BK | BIATC is a Maryland Company | 2013-02-07 | ↗ |
| 18 | Ruane, Cunniff & Goldfarb Inc. | 27.7K | 0.03% | 27.7K | — | 27.7K | — | IA, CO | Delaware | 2017-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
504
-898 vs prev Q
New positions
34
Closed positions
914
Increased
178
Reduced
198
Put/Call ratio
1.14
Calls held
3.5K
Puts held
4.0K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 432.1K +432.1K (+100.0%) | 292.30B +292.3B (+100.0%) | 0.54% +0.539 pp | 0.44% +0.441 pp | USD676.53 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 9.95M -16.7K (-0.2%) | 6.73B +363.7M (+5.7%) | 12.42% +0.028 pp | 0.10% +0.002 pp | USD166.68 +305.9% | 84 qtrs — |
| 3 | BLACKROCK, INC. | 8.53M +329.9K (+4.0%) | 5.77B +532.0M (+10.1%) | 10.66% +0.452 pp | 0.10% +0.006 pp | USD509.67 +32.7% | 6 qtrs — |
| 4 | STATE STREET CORP | 3.66M +139.0K (+4.0%) | 2.47B +226.4M (+10.1%) | 4.57% +0.191 pp | 0.08% +0.005 pp | USD180.89 +274.0% | 51 qtrs — |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.58M +86.3K (+3.5%) | 1.75B +158.3M (+9.9%) | 3.23% +0.120 pp | 0.11% +0.007 pp | USD309.52 +118.6% | 78 qtrs — |
| 6 | FUNDSMITH LLP | 1.88M -734.4K (-28.1%) | 1.27B -398.6M (-23.9%) | 2.34% -0.904 pp | 7.42% -1.010 pp | USD145.16 +366.1% | 44 qtrs — |
| 7 | BAMCO INC /NY/ | 1.80M -86.1K (-4.6%) | 1.22B +12.7M (+1.1%) | 2.24% -0.098 pp | 3.30% +0.104 pp | USD75.78 +792.8% | 84 qtrs — |
| 8 | BANK OF NEW YORK MELLON CORP | 1.62M -432.2K (-21.0%) | 1.10B -215.0M (-16.4%) | 2.03% -0.530 pp | 0.20% -0.060 pp | USD480.41 +40.8% | 66 qtrs — |
| 9 | MORGAN STANLEY | 1.55M -68.8K (-4.2%) | 1.05B +14.6M (+1.4%) | 1.94% -0.078 pp | 0.06% +0.000 pp | USD418.64 +61.6% | 51 qtrs — |
| 10 | INVESCO LTD. | 1.50M +182.0K (+13.8%) | 1.02B +172.8M (+20.5%) | 1.88% +0.234 pp | 0.16% +0.023 pp | USD463.00 +46.1% | 57 qtrs — |
| 11 | BLAIR WILLIAM & CO/IL | 1.00M -30.4K (-2.9%) | 677.46M +18.3M (+2.8%) | 1.25% -0.033 pp | 1.82% +0.064 pp | USD56.20 +1,103.8% | 51 qtrs — |
| 12 | PRINCIPAL FINANCIAL GROUP INC | 968.9K -346.8K (-26.4%) | 655.56M -185.1M (-22.0%) | 1.21% -0.427 pp | 0.33% -0.089 pp | USD370.50 +82.6% | 81 qtrs — |
| 13 | POLEN CAPITAL MANAGEMENT LLC | 960.5K -166.6K (-14.8%) | 649.83M -70.3M (-9.8%) | 1.20% -0.203 pp | 2.77% +0.437 pp | USD536.34 +26.1% | 3 qtrs — |
| 14 | PRICE T ROWE ASSOCIATES INC /MD/ | 952.2K +258.0K (+37.2%) | 644.21M +200.7M (+45.2%) | 1.19% +0.326 pp | 0.07% +0.022 pp | USD539.13 +25.5% | 75 qtrs — |
| 15 | NORTHERN TRUST CORP | 923.2K -19.2K (-2.0%) | 624.54M +22.5M (+3.7%) | 1.15% -0.019 pp | 0.08% +0.003 pp | USD193.25 +250.1% | 51 qtrs — |
| 16 | UBS ASSET MANAGEMENT AMERICAS INC | 859.9K -15.7K (-1.8%) | 581.74M +22.4M (+4.0%) | 1.07% -0.015 pp | 0.12% +0.002 pp | USD367.58 +84.0% | 56 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 832.2K +120.2K (+16.9%) | 563.00M +108.1M (+23.8%) | 1.04% +0.154 pp | 0.07% +0.013 pp | USD491.31 +37.7% | 73 qtrs — |
| 18 | WELLINGTON MANAGEMENT GROUP LLP | 779.2K +592.8K (+318.1%) | 527.16M +408.1M (+342.7%) | 0.97% +0.741 pp | 0.09% +0.072 pp | USD623.22 +8.6% | 30 qtrs — |
| 19 | JPMORGAN CHASE & CO | 673.2K -196.7K (-22.6%) | 455.46M -100.3M (-18.1%) | 0.84% -0.241 pp | 0.03% -0.005 pp | USD506.67 +33.5% | 51 qtrs — |
| 20 | LEGAL & GENERAL GROUP PLC | 670.6K -4.9K (-0.7%) | 453.69M +22.1M (+5.1%) | 0.84% -0.003 pp | 0.10% +0.004 pp | USD308.37 +119.4% | 49 qtrs — |
| 21 | AMERICAN CENTURY COMPANIES INC | 628.9K -76.2K (-10.8%) | 425.49M -25.0M (-5.6%) | 0.79% -0.092 pp | 0.21% -0.015 pp | USD381.62 +77.3% | 40 qtrs — |
| 22 | FRANKLIN RESOURCES INC | 627.2K +54.2K (+9.5%) | 424.29M +58.2M (+15.9%) | 0.78% +0.071 pp | 0.10% +0.013 pp | USD368.25 +83.7% | 46 qtrs — |
| 23 | AMUNDI | 618.7K +26.1K (+4.4%) | 418.60M +46.6M (+12.5%) | 0.77% +0.036 pp | 0.11% -0.006 pp | USD531.11 +27.4% | 19 qtrs — |
| 24 | CAPITAL RESEARCH GLOBAL INVESTORS | 607.8K -82.8K (-12.0%) | 411.16M -30.1M (-6.8%) | 0.76% -0.100 pp | 0.08% -0.007 pp | USD493.01 +37.2% | 9 qtrs — |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 590.1K +14.1K (+2.5%) | 399.19M +31.2M (+8.5%) | 0.74% +0.021 pp | 0.06% +0.003 pp | USD284.94 +137.4% | 67 qtrs — |
| 26 | FUNDSMITH INVESTMENT SERVICES LTD. | 553.9K -134.5K (-19.5%) | 374.70M -65.1M (-14.8%) | 0.69% -0.165 pp | 6.86% +0.001 pp | USD533.51 +26.8% | 16 qtrs — |
| 27 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 550.4K +365.3K (+197.3%) | 372.34M +254.1M (+214.9%) | 0.69% +0.457 pp | 0.22% +0.144 pp | USD629.73 +7.4% | 36 qtrs — |
| 28 | DIMENSIONAL FUND ADVISORS LP | 549.8K +5.6K (+1.0%) | 371.94M +24.3M (+7.0%) | 0.69% +0.010 pp | 0.08% +0.003 pp | USD283.61 +138.5% | 51 qtrs — |
| 29 | NORGES BANK | 491.1K +491.1K (+100.0%) | 332.26M +332.3M (+100.0%) | 0.61% +0.613 pp | 0.04% +0.036 pp | USD676.53 +0.0% | 1 qtrs NEW |
| 30 | BANK OF AMERICA CORP /DE/ | 487.4K -980.0 (-0.2%) | 329.71M +17.7M (+5.7%) | 0.61% +0.001 pp | 0.02% +0.003 pp | USD335.25 +101.8% | 52 qtrs — |
| 31 | NUVEEN, LLC | 466.1K +17.9K (+4.0%) | 315.35M +29.0M (+10.1%) | 0.58% +0.025 pp | 0.08% +0.007 pp | USD438.00 +54.5% | 4 qtrs — |
| 32 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 441.3K -17.7K (-3.9%) | 298.57M +5.3M (+1.8%) | 0.55% -0.020 pp | 0.83% +0.075 pp | USD417.60 +62.0% | 42 qtrs — |
| 33 | CAPITAL COUNSEL LLC/NY | 427.0K -5.6K (-1.3%) | 288.91M +12.5M (+4.5%) | 0.53% -0.005 pp | 11.03% +0.437 pp | USD63.74 +961.4% | 69 qtrs — |
| 34 | ROYAL BANK OF CANADA | 398.3K +60.6K (+17.9%) | 269.48M +53.7M (+24.9%) | 0.50% +0.077 pp | 0.04% +0.009 pp | USD462.34 +46.3% | 51 qtrs — |
| 35 | CIBC PRIVATE WEALTH GROUP, LLC | 362.9K -7.7K (-2.1%) | 245.49M +8.8M (+3.7%) | 0.45% -0.008 pp | 0.42% +0.010 pp | USD501.61 +34.9% | 34 qtrs — |
| 36 | DEUTSCHE BANK AG\ | 357.5K +4.7K (+1.3%) | 241.89M +16.5M (+7.3%) | 0.45% +0.008 pp | 0.08% +0.003 pp | USD415.36 +62.9% | 50 qtrs — |
| 37 | SCHRODER INVESTMENT MANAGEMENT GROUP | 334.8K +11.5K (+3.6%) | 226.49M +22.6M (+11.1%) | 0.42% +0.016 pp | 0.17% +0.014 pp | USD523.94 +29.1% | 39 qtrs — |
| 38 | RAILWAY PENSION INVESTMENTS LTD | 326.1K +29.6K (+10.0%) | 220.60M +31.2M (+16.4%) | 0.41% +0.038 pp | 2.59% +0.025 pp | USD563.68 +20.0% | 29 qtrs — |
| 39 | BESSEMER GROUP INC | 311.3K -40.9K (-11.6%) | 210.64M -14.4M (-6.4%) | 0.39% -0.049 pp | 0.32% -0.021 pp | USD423.15 +59.9% | 51 qtrs — |
| 40 | KBC GROUP NV | 309.4K +134.5K (+76.9%) | 209.31M +97.6M (+87.3%) | 0.39% +0.169 pp | 0.48% +0.209 pp | USD598.49 +13.0% | 68 qtrs — |
| 41 | AUSTRALIANSUPER PTY LTD | 300.2K +204.3K (+213.1%) | 203.09M +141.8M (+231.5%) | 0.37% +0.256 pp | 0.94% +0.662 pp | USD658.20 +2.8% | 3 qtrs — |
| 42 | CLEARBRIDGE INVESTMENTS, LLC | 292.9K +12.1K (+4.3%) | 198.19M +18.8M (+10.5%) | 0.37% +0.017 pp | 0.16% +0.024 pp | USD469.45 +44.1% | 33 qtrs — |
| 43 | UBS GROUP AG | 285.0K -65.9K (-18.8%) | 192.78M -31.4M (-14.0%) | 0.36% -0.081 pp | 0.03% -0.004 pp | USD424.12 +59.5% | 45 qtrs — |
| 44 | NEUBERGER BERMAN GROUP LLC | 274.8K +653.0 (+0.2%) | 185.91M +10.8M (+6.1%) | 0.34% +0.002 pp | 0.14% +0.010 pp | USD127.02 +432.6% | 51 qtrs — |
| 45 | TD ASSET MANAGEMENT INC | 267.9K -36.3K (-11.9%) | 181.21M -13.1M (-6.8%) | 0.33% -0.044 pp | 0.15% -0.012 pp | USD489.88 +38.1% | 51 qtrs — |
| 46 | WILLIAMS JONES WEALTH MANAGEMENT, LLC. | 267.8K -5.1K (-1.9%) | 181.15M +6.8M (+3.9%) | 0.33% -0.005 pp | 2.05% +0.052 pp | USD271.96 +148.8% | 26 qtrs — |
| 47 | RAYMOND JAMES FINANCIAL INC | 256.4K -16.2K (-6.0%) | 174.33M +177.7K (+0.1%) | 0.32% -0.019 pp | 0.05% -0.002 pp | USD472.93 +43.1% | 5 qtrs — |
| 48 | FMR LLC | 251.4K +18.4K (+7.9%) | 170.08M +21.2M (+14.2%) | 0.31% +0.024 pp | 0.01% +0.001 pp | USD454.31 +48.9% | 60 qtrs — |
| 49 | CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 248.7K +94.5K (+61.3%) | 168.25M +69.7M (+70.8%) | 0.31% +0.119 pp | 0.29% +0.108 pp | USD546.20 +23.9% | 39 qtrs — |
| 50 | FIRST TRUST ADVISORS LP | 236.1K +5.9K (+2.6%) | 159.74M +12.7M (+8.6%) | 0.29% +0.009 pp | 0.12% +0.007 pp | USD440.28 +53.7% | 51 qtrs — |
| 51 | BANK JULIUS BAER & CO. LTD, ZURICH | 231.8K +1.4K (+0.6%) | 157.14M +9.9M (+6.7%) | 0.29% +0.003 pp | 0.43% +0.019 pp | USD516.47 +31.0% | 24 qtrs — |
| 52 | SWISS NATIONAL BANK | 219.2K -12.7K (-5.5%) | 148.28M +123.3K (+0.1%) | 0.27% -0.015 pp | 0.09% +0.002 pp | USD230.40 +193.6% | 51 qtrs — |
| 53 | ALLIANZ ASSET MANAGEMENT GMBH | 216.1K +142.0K (+191.6%) | 146.17M +98.8M (+208.8%) | 0.27% +0.178 pp | 0.15% +0.095 pp | USD603.00 +12.2% | 39 qtrs — |
| 54 | BNP PARIBAS ARBITRAGE, SNC | 213.6K +52.6K (+32.7%) | 144.48M +41.6M (+40.5%) | 0.27% +0.066 pp | 0.07% +0.011 pp | USD502.55 +34.6% | 49 qtrs — |
| 55 | BARCLAYS PLC | 211.4K -240.9K (-53.3%) | 143.04M -85.5M (-37.4%) | 0.26% -0.299 pp | 0.03% -0.024 pp | USD526.67 +28.5% | 51 qtrs — |
| 56 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 209.1K +8.6K (+4.3%) | 141.47M +13.4M (+10.4%) | 0.26% +0.012 pp | 0.08% +0.009 pp | USD216.44 +212.6% | 39 qtrs — |
| 57 | COMGEST GLOBAL INVESTORS S.A.S. | 207.1K -37.1K (-15.2%) | 140.09M -15.9M (-10.2%) | 0.26% -0.045 pp | 2.50% -0.268 pp | USD429.69 +57.4% | 17 qtrs — |
| 58 | WELLS FARGO & COMPANY/MN | 205.5K +21.3K (+11.5%) | 139.02M +21.3M (+18.1%) | 0.26% +0.027 pp | 0.03% +0.003 pp | USD466.97 +44.9% | 57 qtrs — |
| 59 | VICTORY CAPITAL MANAGEMENT INC | 205.3K +6.8K (+3.4%) | 138.92M +12.1M (+9.5%) | 0.26% +0.009 pp | 0.08% +0.004 pp | USD429.14 +57.6% | 44 qtrs — |
| 60 | EPOCH INVESTMENT PARTNERS, INC. | 195.8K -36.0K (-15.5%) | 132.46M -15.7M (-10.6%) | 0.24% -0.044 pp | 0.75% -0.061 pp | USD503.69 +34.3% | 28 qtrs — |
| 61 | RUSSELL INVESTMENTS GROUP, LTD. | 194.0K +21.0K (+12.1%) | 131.40M +21.0M (+19.0%) | 0.24% +0.027 pp | 0.14% +0.018 pp | USD465.01 +45.5% | 37 qtrs — |
| 62 | LORD, ABBETT & CO. LLC | 187.0K +119.2K (+175.7%) | 126.52M +83.2M (+192.0%) | 0.23% +0.149 pp | 0.39% +0.259 pp | USD652.19 +3.7% | 4 qtrs — |
| 63 | ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V. | 186.1K -20.4K (-9.9%) | 125.92M -6.0M (-4.6%) | 0.23% -0.024 pp | 0.18% -0.012 pp | USD436.23 +55.1% | 39 qtrs — |
| 64 | CANADA PENSION PLAN INVESTMENT BOARD | 184.4K +26.9K (+17.1%) | 124.78M +24.2M (+24.0%) | 0.23% +0.034 pp | 0.08% +0.013 pp | USD576.15 +17.4% | 49 qtrs — |
| 65 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 184.2K +350.0 (+0.2%) | 123.39M +6.0M (+5.1%) | 0.23% +0.001 pp | 0.08% -0.001 pp | USD455.77 +48.4% | 39 qtrs — |
| 66 | AMERICAN CAPITAL MANAGEMENT INC | 181.7K -2.6K (-1.4%) | 122.96M +5.2M (+4.4%) | 0.23% -0.002 pp | 5.43% +0.734 pp | USD83.53 +709.9% | 54 qtrs — |
| 67 | ENVESTNET ASSET MANAGEMENT INC | 179.9K -22.0K (-10.9%) | 121.71M -7.3M (-5.7%) | 0.22% -0.027 pp | 0.04% -0.001 pp | USD438.56 +54.3% | 45 qtrs — |
| 68 | LOS ANGELES CAPITAL MANAGEMENT LLC | 191.7K +56.2K (+41.5%) | 120.47M +33.9M (+39.2%) | 0.24% +0.071 pp | 0.41% +0.117 pp | USD583.02 +16.0% | 39 qtrs — |
| 69 | AMERIPRISE FINANCIAL INC | 176.9K -20.2K (-10.2%) | 119.70M -6.3M (-5.0%) | 0.22% -0.024 pp | 0.03% -0.002 pp | USD427.58 +58.2% | 55 qtrs — |
| 70 | RHUMBLINE ADVISERS | 173.5K -551.0 (-0.3%) | 117.36M +6.2M (+5.6%) | 0.22% +0.000 pp | 0.09% +0.006 pp | USD171.72 +294.0% | 51 qtrs — |
| 71 | MONTRUSCO BOLTON INVESTMENTS INC. | 176.9K -55.4K (-23.8%) | 117.09M -28.5M (-19.6%) | 0.22% -0.068 pp | 1.46% -0.235 pp | USD458.88 +47.4% | 4 qtrs — |
| 72 | PICTET ASSET MANAGEMENT HOLDING SA | 172.2K -107.2K (-38.4%) | 116.57M -61.9M (-34.7%) | 0.22% -0.133 pp | 0.11% -0.059 pp | USD443.10 +52.7% | 10 qtrs — |
| 73 | WELCH & FORBES LLC | 168.3K -644.0 (-0.4%) | 113.85M +5.9M (+5.5%) | 0.21% +0.000 pp | 1.38% +0.080 pp | USD55.76 +1,113.3% | 88 qtrs — |
| 74 | TIMESSQUARE CAPITAL MANAGEMENT, LLC | 167.3K -25.7K (-13.3%) | 113.15M -10.1M (-8.2%) | 0.21% -0.031 pp | 1.70% -0.058 pp | USD407.60 +66.0% | 15 qtrs — |
| 75 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 162.6K +5.0K (+3.2%) | 110.00M +9.3M (+9.3%) | 0.20% +0.007 pp | 0.06% +0.003 pp | USD221.99 +204.8% | 54 qtrs — |
| 76 | HSBC HOLDINGS PLC | 159.6K -33.5K (-17.3%) | 108.05M -15.2M (-12.3%) | 0.20% -0.041 pp | 0.06% -0.013 pp | USD465.17 +45.4% | 44 qtrs — |
| 77 | PRUDENTIAL FINANCIAL INC | 158.6K -19.9K (-11.2%) | 107.31M -6.8M (-5.9%) | 0.20% -0.024 pp | 0.13% -0.006 pp | USD595.65 +13.6% | 85 qtrs — |
| 78 | CONGRESS ASSET MANAGEMENT CO /MA | 153.9K +152.4K (+9,894.0%) | 104.12M +103.1M (+10,482.8%) | 0.19% +0.190 pp | 0.73% +0.726 pp | USD672.88 +0.5% | 73 qtrs — |
| 79 | LIONTRUST INVESTMENT PARTNERS LLP | 150.8K -14.9K (-9.0%) | 102.01M -3.9M (-3.6%) | 0.19% -0.018 pp | 1.51% +0.025 pp | USD419.74 +61.2% | 5 qtrs — |
| 80 | WESTFIELD CAPITAL MANAGEMENT CO LP | 147.4K +53.3K (+56.6%) | 99.75M +39.6M (+65.9%) | 0.18% +0.067 pp | 0.42% +0.163 pp | USD652.50 +3.7% | 2 qtrs — |
| 81 | PROSHARE ADVISORS LLC | 147.3K +38.3K (+35.2%) | 99.67M +30.0M (+43.1%) | 0.18% +0.048 pp | 0.18% +0.030 pp | USD511.58 +32.2% | 70 qtrs — |
| 82 | FEDERATED HERMES, INC. | 140.3K +31.4K (+28.9%) | 94.90M +25.4M (+36.5%) | 0.18% +0.040 pp | 0.16% +0.036 pp | USD558.32 +21.2% | 54 qtrs — |
| 83 | SEI INVESTMENTS CO | 135.9K +32.5K (+31.4%) | 91.93M +25.9M (+39.2%) | 0.17% +0.041 pp | 0.09% +0.020 pp | USD533.36 +26.8% | 45 qtrs — |
| 84 | BANK OF MONTREAL /CAN/ | 133.8K -5.3K (-3.8%) | 90.52M +1.6M (+1.8%) | 0.17% -0.006 pp | 0.03% -0.003 pp | USD475.72 +42.2% | 51 qtrs — |
| 85 | SELECT EQUITY GROUP, L.P. | 131.4K -150.6K (-53.4%) | 88.89M -91.3M (-50.7%) | 0.16% -0.187 pp | 0.38% -0.359 pp | USD442.22 +53.0% | 4 qtrs — |
| 86 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | 124.0K -3.1K (-2.4%) | 86.18M +5.0M (+6.2%) | 0.15% -0.003 pp | 0.78% +0.069 pp | USD105.94 +538.6% | 55 qtrs — |
| 87 | EULAV ASSET MANAGEMENT | 126.2K -2.0 (0.0%) | 85.39M +4.7M (+5.9%) | 0.16% +0.001 pp | 2.28% +0.404 pp | USD286.52 +136.1% | 57 qtrs — |
| 88 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 125.4K -1.3K (-1.0%) | 84.84M +3.9M (+4.8%) | 0.16% -0.001 pp | 0.08% +0.002 pp | USD132.88 +409.1% | 52 qtrs — |
| 89 | VOYA INVESTMENT MANAGEMENT LLC | 117.2K +3.0K (+2.6%) | 79.28M +6.3M (+8.7%) | 0.15% +0.004 pp | 0.08% +0.005 pp | USD503.67 +34.3% | 51 qtrs — |
| 90 | CITIGROUP INC | 117.0K -27.4K (-19.0%) | 79.16M -13.1M (-14.2%) | 0.15% -0.034 pp | 0.03% -0.006 pp | USD462.28 +46.3% | 108 qtrs — |
| 91 | AQR CAPITAL MANAGEMENT LLC | 114.8K -20.4K (-15.1%) | 77.65M -7.8M (-9.1%) | 0.14% -0.025 pp | 0.04% -0.014 pp | USD463.09 +46.1% | 61 qtrs — |
| 92 | CI PRIVATE WEALTH, LLC | 114.6K -1.6K (-1.3%) | 77.63M +3.4M (+4.6%) | 0.14% -0.001 pp | 0.10% -0.013 pp | USD497.20 +36.1% | 13 qtrs — |
| 93 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 114.2K +909.0 (+0.8%) | 77.43M +5.1M (+7.0%) | 0.14% +0.002 pp | 0.13% +0.006 pp | USD433.84 +55.9% | 5 qtrs — |
| 94 | KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC | 113.1K -17.1K (-13.1%) | 76.52M -6.7M (-8.0%) | 0.14% -0.021 pp | 0.21% +0.003 pp | USD393.39 +72.0% | 25 qtrs — |
| 95 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 109.9K +9.0K (+8.9%) | 74.34M +9.9M (+15.4%) | 0.14% +0.012 pp | 0.09% -0.082 pp | USD478.22 +41.5% | 39 qtrs — |
| 96 | RATHBONES GROUP PLC | 108.9K -8.7K (-7.4%) | 73.66M -1.5M (-1.9%) | 0.14% -0.010 pp | 0.29% -0.013 pp | USD379.40 +78.3% | 30 qtrs — |
| 97 | BROWN ADVISORY INC | 107.6K -1.2K (-1.1%) | 72.78M +3.3M (+4.7%) | 0.13% -0.001 pp | 0.10% +0.011 pp | USD354.87 +90.6% | 62 qtrs — |
| 98 | NATIONAL PENSION SERVICE | 106.3K -10.7K (-9.2%) | 71.94M -2.9M (-3.8%) | 0.13% -0.013 pp | 0.05% -0.005 pp | USD316.71 +113.6% | 38 qtrs — |
| 99 | ELYXIUM WEALTH, LLC | 5.42M +5.4M (+100.0%) | 5.44M +5.4M (+100.0%) | 6.77% +6.766 pp | 1.51% +1.510 pp | USD676.53 +0.0% | 1 qtrs NEW |
| 100 | J. STERN & CO. LLP | 2.65M +2.6M (+23,694.7%) | 2.65M -4.5M (-62.8%) | 3.31% +3.299 pp | 0.23% -0.313 pp | USD676.07 +0.1% | 9 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.98
Neutral
Ratio by volume
1.31
Neutral
Buys
90
Sells
92
Shares acquired
142.8K
Shares disposed
109.2K
Cash buys
—
Cash sales
31.00
Net activity
+33,581
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | HOOLEY JOSEPH L | Director | A-Award | A | Common Stock | 43 | 560.80 | 24.1K | 118 | D | ↗ |
| 2026-03-03 | Underberg Sharon E. | Officer | M-Exempt | A | Common Stock | 197 | 505.53 | 99.6K | 7,138 | D | ↗ |
| 2026-03-03 | Hunt Nimrata | Officer | S-Sale | D | Common Stock | 1,758 | 634.57 | 1.12M | 18,141 | D | ↗ |
| 2026-02-27 | MAZELSKY JONATHAN JAY | Director / Officer | M-Exempt | D | Incentive Stock Option (right-to-buy) | 197 | 505.53 | 99.6K | 0 | D | ↗ |
| 2026-02-26 | MAZELSKY JONATHAN JAY | Director / Officer | S-Sale | D | Common Stock | 1,343 | 656.85 | 882.1K | 97,774 | D | ↗ |
| 2026-02-26 | Hunt Nimrata | Officer | S-Sale | D | Common Stock | 2,693 | 661.54 | 1.78M | 19,899 | D | ↗ |
| 2026-02-19 | Erickson Michael G | Officer | M-Exempt | A | Common Stock | 183 | 544.08 | 99.6K | 14,895 | D | ↗ |
| 2026-02-17 | Vandebroek Sophie V. | Director | M-Exempt | D | Non-Qualified Stock Option (right-to-buy) | 945 | 333.90 | 315.5K | 0 | D | ↗ |
| 2026-02-17 | Erickson Michael G | Officer | S-Sale | D | Common Stock | 456 | 623.76 | 284.4K | 17,608 | D | ↗ |
| 2026-02-14 | Underberg Sharon E. | Officer | M-Exempt | D | Restricted Stock Unit | 265 | 0.00 | — | 795 | D | ↗ |
| 2026-02-14 | Smith Martin Alexander | Officer | M-Exempt | D | Restricted Stock Unit | 301 | 0.00 | — | 602 | D | ↗ |
| 2026-02-14 | Schreck Michael | Officer | M-Exempt | A | Common Stock | 117 | 0.00 | — | 2,123 | D | ↗ |
| 2026-02-14 | MAZELSKY JONATHAN JAY | Director / Officer | M-Exempt | A | Common Stock | 958 | 0.00 | — | 83,422 | D | ↗ |
| 2026-02-14 | Lane Michael | Officer | M-Exempt | D | Restricted Stock Unit | 204 | 0.00 | — | 0 | D | ↗ |
| 2026-02-14 | Johnson Michael Perkins | Officer | F-InKind | D | Common Stock | 178 | 629.35 | 112.0K | 2,795 | D | ↗ |
| 2026-02-14 | Hunt Nimrata | Officer | M-Exempt | A | Common Stock | 301 | 0.00 | — | 21,871 | D | ↗ |
| 2026-02-14 | FENNELL GEORGE | Officer | M-Exempt | A | Common Stock | 139 | 0.00 | — | 10,073 | D | ↗ |
| 2026-02-14 | Erickson Michael G | Officer | M-Exempt | D | Restricted Stock Unit | 1,508 | 0.00 | — | 0 | D | ↗ |
| 2026-02-14 | Emerson Andrew | Officer | M-Exempt | D | Restricted Stock Unit | 94 | 0.00 | — | 93 | D | ↗ |
| 2026-02-12 | Underberg Sharon E. | Officer | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 3,738 | 617.20 | 2.31M | 3,738 | D | ↗ |
| 2026-02-12 | Smith Martin Alexander | Officer | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 5,361 | 617.20 | 3.31M | 5,361 | D | ↗ |
| 2026-02-12 | Schreck Michael | Officer | A-Award | A | Incentive Stock Option (right-to-buy) | 162 | 617.20 | 100.0K | 162 | D | ↗ |
| 2026-02-12 | MAZELSKY JONATHAN JAY | Director / Officer | A-Award | A | Restricted Stock Unit | 13,407 | 0.00 | — | 13,407 | D | ↗ |
| 2026-02-12 | Lane Michael | Officer | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 5,361 | 617.20 | 3.31M | 5,361 | D | ↗ |
| 2026-02-12 | Johnson Michael Perkins | Officer | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 3,207 | 617.20 | 1.98M | 3,207 | D | ↗ |
| 2026-02-12 | Hunt Nimrata | Officer | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 4,625 | 617.20 | 2.85M | 4,625 | D | ↗ |
| 2026-02-12 | FENNELL GEORGE | Officer | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 3,384 | 617.20 | 2.09M | 3,384 | D | ↗ |
| 2026-02-12 | Erickson Michael G | Officer | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 13,667 | 617.20 | 8.44M | 13,667 | D | ↗ |
| 2026-02-12 | Emerson Andrew | Officer | A-Award | A | Restricted Stock Unit | 729 | 0.00 | — | 729 | D | ↗ |
| 2026-02-10 | FENNELL GEORGE | Officer | S-Sale | D | Common Stock | 40 | 650.32 | 26.0K | 9,823 | D | ↗ |
| 2026-02-09 | FENNELL GEORGE | Officer | M-Exempt | D | Incentive Stock Option (right-to-buy) | 1,476 | 67.85 | 100.1K | 0 | D | ↗ |
| 2026-01-30 | HOOLEY JOSEPH L | Director | A-Award | A | Common Stock | 36 | 670.46 | 24.1K | 75 | D | ↗ |
| 2025-12-01 | Peacock Karen | Director | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 231 | 727.97 | 168.2K | 231 | D | ↗ |
| 2025-11-07 | Hunt Nimrata | Officer | S-Sale | D | Common Stock | 1,465 | 703.73 | 1.03M | 23,995 | D | ↗ |
| 2025-10-30 | HOOLEY JOSEPH L | Director | A-Award | A | Common Stock | 39 | 628.54 | 24.5K | 39 | D | ↗ |
| 2025-10-06 | Peacock Karen | Director | — | — | Common Stock | 0 | 0.00 | — | 1 | D | ↗ |
| 2025-09-01 | Smith Martin Alexander | Officer | M-Exempt | A | Common Stock | 18 | 0.00 | — | 1,439 | D | ↗ |
| 2025-09-01 | HOOLEY JOSEPH L | Director | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 364 | 647.09 | 235.5K | 364 | D | ↗ |
| 2025-08-22 | SZOSTAK M ANNE | Director | G-Gift | D | Common Stock | 259 | 0.00 | — | 1,542 | I | ↗ |
| 2025-08-15 | MAZELSKY JONATHAN JAY | Director / Officer | G-Gift | D | Common Stock | 1,051 | 0.00 | — | 82,443 | D | ↗ |
| 2025-08-12 | Underberg Sharon E. | Officer | M-Exempt | D | Incentive Stock Option (right-to-buy) | 183 | 544.08 | 99.6K | 0 | D | ↗ |
| 2025-08-12 | Hunt Nimrata | Officer | M-Exempt | A | Common Stock | 183 | 544.08 | 99.6K | 18,033 | D | ↗ |
| 2025-08-12 | Erickson Michael G | Officer | S-Sale | D | Common Stock | 318 | 649.99 | 206.7K | 11,375 | D | ↗ |
| 2025-08-11 | Hunt Nimrata | Officer | S-Sale | D | Common Stock | 1,200 | 656.53 | 787.8K | 16,807 | D | ↗ |
| 2025-08-08 | Underberg Sharon E. | Officer | M-Exempt | D | Non-Qualified Stock Option (right-to-buy) | 5,450 | 206.94 | 1.13M | 0 | D | ↗ |
| 2025-08-08 | MAZELSKY JONATHAN JAY | Director / Officer | M-Exempt | D | Premium Incentive Stock Option (right-to-buy) | 183 | 598.49 | 109.5K | 0 | D | ↗ |
| 2025-08-07 | Emerson Andrew | Officer | M-Exempt | A | Common Stock | 1,849 | 141.60 | 261.8K | 4,273 | D | ↗ |
| 2025-08-06 | MAZELSKY JONATHAN JAY | Director / Officer | S-Sale | D | Common Stock | 3,526 | 635.13 | 2.24M | 86,673 | D | ↗ |
| 2025-08-06 | Lane Michael | Officer | M-Exempt | A | Common Stock | 7,125 | 288.78 | 2.06M | 15,543 | D | ↗ |
| 2025-08-06 | Hunt Nimrata | Officer | M-Exempt | D | Non-Qualified Stock Option (right-to-buy) | 5,865 | 178.26 | 1.05M | 0 | D | ↗ |
| 2025-07-10 | HOOLEY JOSEPH L | Director | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-06-01 | Johnson Michael Perkins | Officer | M-Exempt | A | Common Stock | 3,382 | 0.00 | — | 3,864 | D | ↗ |
| 2025-05-21 | SZOSTAK M ANNE | Director | S-Sale | D | Common Stock | 1,260 | 512.34 | 645.5K | 1,801 | I | ↗ |
| 2025-05-13 | JUNIUS DANIEL M | Director | M-Exempt | D | Non-Qualified Stock Option (right-to-buy) | 1,404 | 245.79 | 345.1K | 0 | D | ↗ |
| 2025-05-09 | Vandebroek Sophie V. | Director | M-Exempt | A | Common Stock | 1,279 | 283.59 | 362.7K | 2,446 | D | ↗ |
| 2025-05-07 | Vandebroek Sophie V. | Director | A-Award | A | Restricted Stock Unit | 257 | 0.00 | — | 257 | D | ↗ |
| 2025-05-07 | SZOSTAK M ANNE | Director | A-Award | A | Restricted Stock Unit | 257 | 0.00 | — | 257 | D | ↗ |
| 2025-05-07 | SAMAD SAM | Director | A-Award | A | Deferred Stock Unit | 257 | 0.00 | — | 257 | D | ↗ |
| 2025-05-07 | Kingsley Lawrence D | Director | A-Award | A | Restricted Stock Unit | 82 | 0.00 | — | 82 | D | ↗ |
| 2025-05-07 | JUNIUS DANIEL M | Director | A-Award | A | Restricted Stock Unit | 257 | 0.00 | — | 257 | D | ↗ |
| 2025-05-07 | ESSIG STUART | Director | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 600 | 486.61 | 292.0K | 600 | D | ↗ |
| 2025-05-07 | Claflin Bruce L. | Director | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 600 | 486.61 | 292.0K | 600 | D | ↗ |
| 2025-05-07 | Britt Irene Chang | Director | A-Award | A | Deferred Stock Unit | 257 | 0.00 | — | 257 | D | ↗ |
| 2025-05-06 | Vandebroek Sophie V. | Director | M-Exempt | A | Common Stock | 262 | 0.00 | — | 1,167 | D | ↗ |
| 2025-05-06 | SZOSTAK M ANNE | Director | M-Exempt | D | Restricted Stock Unit | 262 | 0.00 | — | 0 | D | ↗ |
| 2025-05-06 | Kingsley Lawrence D | Director | M-Exempt | A | Common Stock | 262 | 0.00 | — | 9,145 | D | ↗ |
| 2025-05-06 | JUNIUS DANIEL M | Director | M-Exempt | D | Restricted Stock Unit | 262 | 0.00 | — | 0 | D | ↗ |
| 2025-05-06 | ESSIG STUART | Director | M-Exempt | A | Common Stock | 262 | 0.00 | — | 2,236 | D | ↗ |
| 2025-03-01 | Emerson Andrew | Officer | — | — | Incentive Stock Option (right-to-buy) | 1,849 | 141.60 | 261.8K | 0 | D | ↗ |
| 2025-02-14 | Underberg Sharon E. | Officer | M-Exempt | D | Restricted Stock Unit | 137 | 0.00 | — | 0 | D | ↗ |
| 2025-02-14 | Smith Martin Alexander | Officer | M-Exempt | D | Restricted Stock Unit | 189 | 0.00 | — | 376 | D | ↗ |
| 2025-02-14 | Schreck Michael | Officer | M-Exempt | D | Restricted Stock Unit | 791 | 0.00 | — | 0 | D | ↗ |
| 2025-02-14 | MCKEON BRIAN P | Officer | M-Exempt | D | Restricted Stock Unit | 252 | 0.00 | — | 0 | D | ↗ |
| 2025-02-14 | MAZELSKY JONATHAN JAY | Director / Officer | F-InKind | D | Common Stock | 1,222 | 444.53 | 543.2K | 83,283 | D | ↗ |
| 2025-02-14 | Lane Michael | Officer | M-Exempt | D | Restricted Stock Unit | 204 | 0.00 | — | 204 | D | ↗ |
| 2025-02-14 | Johnson Michael Perkins | Officer | M-Exempt | D | Restricted Stock Unit | 179 | 0.00 | — | 535 | D | ↗ |
| 2025-02-14 | Hunt Nimrata | Officer | M-Exempt | A | Common Stock | 301 | 0.00 | — | 12,595 | D | ↗ |
| 2025-02-14 | FENNELL GEORGE | Officer | M-Exempt | D | Restricted Stock Unit | 56 | 0.00 | — | 55 | D | ↗ |
| 2025-02-14 | Erickson Michael G | Officer | M-Exempt | D | Restricted Stock Unit | 93 | 0.00 | — | 92 | D | ↗ |
| 2025-02-13 | Underberg Sharon E. | Officer | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 4,504 | 459.76 | 2.07M | 4,504 | D | ↗ |
| 2025-02-13 | Smith Martin Alexander | Officer | A-Award | A | Incentive Stock Option (right-to-buy) | 217 | 459.76 | 99.8K | 217 | D | ↗ |
| 2025-02-13 | Schreck Michael | Officer | A-Award | A | Incentive Stock Option (right-to-buy) | 217 | 459.76 | 99.8K | 217 | D | ↗ |
| 2025-02-13 | MAZELSKY JONATHAN JAY | Director / Officer | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 25,932 | 459.76 | 11.92M | 25,932 | D | ↗ |
| 2025-02-13 | Lane Michael | Officer | A-Award | A | Incentive Stock Option (right-to-buy) | 217 | 459.76 | 99.8K | 217 | D | ↗ |
| 2025-02-13 | Johnson Michael Perkins | Officer | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 3,657 | 459.76 | 1.68M | 3,657 | D | ↗ |
| 2025-02-13 | Hunt Nimrata | Officer | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 6,320 | 459.76 | 2.91M | 6,320 | D | ↗ |
| 2025-02-13 | FENNELL GEORGE | Officer | A-Award | A | Incentive Stock Option (right-to-buy) | 217 | 459.76 | 99.8K | 217 | D | ↗ |
| 2025-02-13 | Erickson Michael G | Officer | A-Award | A | Incentive Stock Option (right-to-buy) | 217 | 459.76 | 99.8K | 217 | D | ↗ |
| 2025-02-11 | Erickson Michael G | Officer | M-Exempt | D | Incentive Stock Option (right-to-buy) | 1,544 | 67.85 | 104.8K | 0 | D | ↗ |
| 2025-02-10 | FENNELL GEORGE | Officer | S-Sale | D | Common Stock | 9,986 | 462.53 | 4.62M | 8,176 | D | ↗ |
| 2025-02-07 | SZOSTAK M ANNE | Director | S-Sale | D | Common Stock | 3,000 | 465.95 | 1.40M | 3,061 | I | ↗ |
| 2025-02-07 | FENNELL GEORGE | Officer | M-Exempt | A | Common Stock | 1,256 | 79.54 | 99.9K | 8,176 | D | ↗ |
| 2024-12-31 | Erickson Michael G | Officer | — | — | Common Stock | 0 | 0.00 | — | 9,742 | D | ↗ |
| 2024-11-27 | Vandebroek Sophie V. | Director | G-Gift | D | Common Stock | 224 | 0.00 | — | 1,249 | D | ↗ |
| 2024-09-06 | SZOSTAK M ANNE | Director | S-Sale | D | Common Stock | 500 | 469.37 | 234.7K | 0 | — | ↗ |
| 2024-09-06 | AYERS JONATHAN W | Director | G-Gift | A | Common Stock | 112,605 | 0.00 | — | 122,605 | — | ↗ |
| 2024-09-05 | SZOSTAK M ANNE | Director | G-Gift | D | Common Stock | 500 | 0.00 | — | 6,061 | — | ↗ |
| 2024-09-01 | Smith Martin Alexander | Officer | M-Exempt | A | Common Stock | 18 | 0.00 | — | 515 | — | ↗ |
| 2024-09-01 | Schreck Michael | Officer | M-Exempt | A | Common Stock | 164 | 0.00 | — | 961 | — | ↗ |
| 2024-08-05 | MCKEON BRIAN P | Officer | M-Exempt | D | Restricted Stock Unit | 192 | 0.00 | — | 0 | — | ↗ |
| 2024-08-05 | MAZELSKY JONATHAN JAY | Director / Officer | M-Exempt | A | Common Stock | 384 | 0.00 | — | 81,903 | — | ↗ |
| 2024-05-17 | Claflin Bruce L. | Director | S-Sale | D | Common Stock | 200 | 540.80 | 108.2K | 161 | — | ↗ |
| 2024-05-08 | SZOSTAK M ANNE | Director | G-Gift | A | Common Stock | 257 | 0.00 | — | 6,561 | — | ↗ |
| 2024-05-06 | Vandebroek Sophie V. | Director | M-Exempt | A | Common Stock | 257 | 0.00 | — | 1,473 | — | ↗ |
| 2024-05-06 | SZOSTAK M ANNE | Director | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 609 | 476.87 | 290.4K | 609 | — | ↗ |
| 2024-05-06 | SAMAD SAM | Director | A-Award | A | Deferred Stock Unit | 262 | 0.00 | — | 863 | — | ↗ |
| 2024-05-06 | Kingsley Lawrence D | Director | M-Exempt | A | Common Stock | 82 | 0.00 | — | 8,883 | — | ↗ |
| 2024-05-06 | JUNIUS DANIEL M | Director | A-Award | A | Restricted Stock Unit | 262 | 0.00 | — | 262 | — | ↗ |
| 2024-05-06 | ESSIG STUART | Director | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 609 | 476.87 | 290.4K | 609 | — | ↗ |
| 2024-05-06 | Claflin Bruce L. | Director | A-Award | A | Deferred Stock Unit | 262 | 0.00 | — | 863 | — | ↗ |
| 2024-05-06 | COLLINS Asha | Director | M-Exempt | A | Common Stock | 257 | 0.00 | — | 779 | — | ↗ |
| 2024-05-06 | Britt Irene Chang | Director | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 609 | 476.87 | 290.4K | 609 | — | ↗ |
| 2024-05-06 | AYERS JONATHAN W | Director | M-Exempt | D | Restricted Stock Unit | 257 | 0.00 | — | 0 | — | ↗ |
| 2024-03-06 | POLEWACZYK JAMES F | Officer | S-Sale | D | Common Stock | 3,290 | 558.88 | 1.84M | 11,391 | — | ↗ |
| 2024-03-05 | Vandebroek Sophie V. | Director | M-Exempt | A | Common Stock | 1,404 | 245.79 | 345.1K | 2,620 | — | ↗ |
| 2024-02-29 | MAZELSKY JONATHAN JAY | Director / Officer | G-Gift | D | Common Stock | 550 | 0.00 | — | 81,497 | — | ↗ |
| 2024-02-21 | MAZELSKY JONATHAN JAY | Director / Officer | M-Exempt | D | Incentive Stock Option (right-to-buy) | 483 | 206.94 | 100.0K | 0 | — | ↗ |
| 2024-02-16 | Underberg Sharon E. | Officer | M-Exempt | A | Common Stock | 483 | 206.94 | 100.0K | 5,595 | — | ↗ |
| 2024-02-15 | MCKEON BRIAN P | Officer | M-Exempt | A | Common Stock | 483 | 206.94 | 100.0K | 30,835 | — | ↗ |
| 2024-02-14 | Underberg Sharon E. | Officer | A-Award | A | Incentive Stock Option (right-to-buy) | 178 | 560.56 | 99.8K | 178 | — | ↗ |
| 2024-02-14 | Smith Martin Alexander | Officer | A-Award | A | Restricted Stock Unit | 1,204 | 0.00 | — | 1,204 | — | ↗ |
| 2024-02-14 | Schreck Michael | Officer | M-Exempt | D | Restricted Stock Unit | 170 | 0.00 | — | 508 | — | ↗ |
| 2024-02-14 | POLEWACZYK JAMES F | Officer | M-Exempt | A | Common Stock | 220 | 0.00 | — | 10,990 | — | ↗ |
| 2024-02-14 | MCKEON BRIAN P | Officer | F-InKind | D | Common Stock | 1,097 | 560.56 | 614.9K | 30,352 | — | ↗ |
| 2024-02-14 | MAZELSKY JONATHAN JAY | Director / Officer | A-Award | A | Incentive Stock Option (right-to-buy) | 178 | 560.56 | 99.8K | 178 | — | ↗ |
| 2024-02-14 | MAZELSKY JAY | Officer | A-Award | A | Incentive Stock Option (right to buy) | 806 | 124.00 | 99.9K | 806 | — | ↗ |
| 2024-02-14 | Lane Michael | Officer | M-Exempt | D | Restricted Stock Unit | 173 | 0.00 | — | 0 | — | ↗ |
| 2024-02-14 | Johnson Michael Perkins | Officer | A-Award | A | Restricted Stock Unit | 714 | 0.00 | — | 714 | — | ↗ |
| 2024-02-14 | Hunt Nimrata | Officer | M-Exempt | D | Restricted Stock Unit | 208 | 0.00 | — | 621 | — | ↗ |
| 2024-02-14 | FENNELL GEORGE | Officer | M-Exempt | D | Restricted Stock Unit | 97 | 0.00 | — | 0 | — | ↗ |
| 2024-02-14 | Erickson Michael G | Officer | M-Exempt | D | Restricted Stock Unit | 97 | 0.00 | — | 0 | — | ↗ |
| 2024-02-09 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 5,350 | 0.00 | — | 265,394 | — | ↗ |
| 2024-02-08 | FENNELL GEORGE | Officer | S-Sale | D | Common Stock | 3,173 | 575.02 | 1.82M | 7,124 | — | ↗ |
| 2024-02-08 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 850 | 0.00 | — | 270,744 | — | ↗ |
| 2024-02-07 | MCKEON BRIAN P | Officer | S-Sale | D | Common Stock | 7,128 | 571.84 | 4.08M | 30,399 | — | ↗ |
| 2024-02-07 | MAZELSKY JONATHAN JAY | Director / Officer | S-Sale | D | Common Stock | 705 | 575.48 | 405.7K | 79,247 | — | ↗ |
| 2024-02-07 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 1,000 | 0.00 | — | 271,594 | — | ↗ |
| 2024-01-30 | JUNIUS DANIEL M | Director | A-Award | A | Common Stock | 14 | 521.03 | 7.3K | 3,042 | — | ↗ |
| 2024-01-01 | Schreck Michael | Officer | — | D | Common Stock | 0 | 0.00 | — | 535 | — | ↗ |
| 2024-01-01 | FENNELL GEORGE | Officer | — | D | Incentive Stock Option (right-to-buy) | 560 | 178.26 | 99.8K | 0 | — | ↗ |
| 2024-01-01 | Erickson Michael G | Officer | — | D | Non-Qualified Stock Option (right-to-buy) | 4,008 | 288.78 | 1.16M | 0 | — | ↗ |
| 2023-12-07 | POLEWACZYK JAMES F | Officer | S-Sale | D | Common Stock | 1,202 | 522.31 | 627.8K | 13,990 | — | ↗ |
| 2023-12-04 | MAZELSKY JONATHAN JAY | Director / Officer | M-Exempt | A | Common Stock | 13,424 | 79.54 | 1.07M | 86,361 | — | ↗ |
| 2023-12-04 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 2,424 | 0.00 | — | 272,594 | — | ↗ |
| 2023-11-29 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 1,850 | 0.00 | — | 275,018 | — | ↗ |
| 2023-11-20 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 2,506 | 0.00 | — | 276,868 | — | ↗ |
| 2023-11-15 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 2,494 | 0.00 | — | 279,374 | — | ↗ |
| 2023-11-07 | Lane Michael | Officer | M-Exempt | D | Incentive Stock Option (right-to-buy) | 560 | 178.26 | 99.8K | 0 | — | ↗ |
| 2023-10-30 | JUNIUS DANIEL M | Director | A-Award | A | Common Stock | 19 | 396.39 | 7.5K | 3,028 | — | ↗ |
| 2023-09-06 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 147,821 | 0.00 | — | 302,179 | — | ↗ |
| 2023-09-01 | Smith Martin Alexander | Officer | M-Exempt | A | Common Stock | 19 | 0.00 | — | 226 | — | ↗ |
| 2023-09-01 | Britt Irene Chang | Director | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 493 | 511.29 | 252.1K | 493 | — | ↗ |
| 2023-09-01 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 250 | 0.00 | — | 134,047 | — | ↗ |
| 2023-08-31 | MAZELSKY JONATHAN JAY | Director / Officer | S-Sale | D | Common Stock | 13,424 | 512.01 | 6.87M | 72,925 | — | ↗ |
| 2023-08-31 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 1,250 | 0.00 | — | 134,297 | — | ↗ |
| 2023-08-29 | POLEWACZYK JAMES F | Officer | M-Exempt | A | Common Stock | 2,627 | 68.75 | 180.6K | 18,665 | — | ↗ |
| 2023-08-15 | AYERS JONATHAN W | Director | S-Sale | D | Common Stock | 492 | 0.00 | — | 135,547 | — | ↗ |
| 2023-08-11 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 1,000 | 0.00 | — | 136,039 | — | ↗ |
| 2023-08-05 | MCKEON BRIAN P | Officer | M-Exempt | A | Common Stock | 192 | 0.00 | — | 29,809 | — | ↗ |
| 2023-08-05 | MAZELSKY JONATHAN JAY | Director / Officer | M-Exempt | A | Common Stock | 384 | 0.00 | — | 73,095 | — | ↗ |
| 2023-08-03 | Lane Michael | Officer | S-Sale | D | Common Stock | 16,027 | 510.00 | 8.17M | 4,034 | — | ↗ |
| 2023-07-28 | JUNIUS DANIEL M | Director | A-Award | A | Common Stock | 14 | 552.78 | 7.7K | 3,009 | — | ↗ |
| 2023-07-11 | Britt Irene Chang | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-19 | AYERS JONATHAN W | Director | S-Sale | D | Common Stock | 300 | 490.03 | 147.0K | 142,039 | — | ↗ |
| 2023-05-18 | MAZELSKY JONATHAN JAY | Director / Officer | G-Gift | D | Common Stock | 602 | 0.00 | — | 72,699 | — | ↗ |
| 2023-05-18 | AYERS JONATHAN W | Director | S-Sale | D | Common Stock | 1,000 | 486.48 | 486.5K | 146,039 | — | ↗ |
| 2023-05-17 | Vandebroek Sophie V. | Director | A-Award | A | Restricted Stock Unit | 257 | 0.00 | — | 257 | — | ↗ |
| 2023-05-17 | SZOSTAK M ANNE | Director | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 645 | 487.12 | 314.2K | 645 | — | ↗ |
| 2023-05-17 | SAMAD SAM | Director | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 645 | 487.12 | 314.2K | 645 | — | ↗ |
| 2023-05-17 | Kingsley Lawrence D | Director | A-Award | A | Restricted Stock Unit | 257 | 0.00 | — | 257 | — | ↗ |
| 2023-05-17 | JUNIUS DANIEL M | Director | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 645 | 487.12 | 314.2K | 645 | — | ↗ |
| 2023-05-17 | ESSIG STUART | Director | A-Award | A | Restricted Stock Unit | 257 | 0.00 | — | 257 | — | ↗ |
| 2023-05-17 | Claflin Bruce L. | Director | A-Award | A | Deferred Stock Unit | 257 | 0.00 | — | 601 | — | ↗ |
| 2023-05-17 | COLLINS Asha | Director | A-Award | A | Non-Qualified Stock Option (right-to-buy) | 645 | 487.12 | 314.2K | 645 | — | ↗ |
| 2023-05-17 | AYERS JONATHAN W | Director | A-Award | A | Restricted Stock Unit | 257 | 0.00 | — | 257 | — | ↗ |
| 2023-05-15 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 3,514 | 0.00 | — | 137,039 | — | ↗ |
| 2023-05-11 | Vandebroek Sophie V. | Director | M-Exempt | D | Restricted Stock Unit | 344 | 0.00 | — | 0 | — | ↗ |
| 2023-05-11 | SZOSTAK M ANNE | Director | M-Exempt | D | Restricted Stock Unit | 344 | 0.00 | — | 0 | — | ↗ |
| 2023-05-11 | Kingsley Lawrence D | Director | M-Exempt | A | Common Stock | 344 | 0.00 | — | 8,424 | — | ↗ |
| 2023-05-11 | ESSIG STUART | Director | M-Exempt | A | Common Stock | 344 | 0.00 | — | 1,717 | — | ↗ |
| 2023-05-11 | COLLINS Asha | Director | M-Exempt | D | Restricted Stock Unit | 344 | 0.00 | — | 0 | — | ↗ |
| 2023-05-11 | AYERS JONATHAN W | Director | M-Exempt | D | Restricted Stock Unit | 344 | 0.00 | — | 0 | — | ↗ |
| 2023-05-10 | AYERS JONATHAN W | Director | M-Exempt | A | Common Stock | 560 | 178.26 | 99.8K | 141,894 | — | ↗ |
| 2023-05-09 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 1,685 | 0.00 | — | 141,334 | — | ↗ |
| 2023-05-05 | Underberg Sharon E. | Officer | M-Exempt | D | Common Stock | 483 | 206.92 | 99.9K | 483 | — | ↗ |
| 2023-05-05 | SZOSTAK M ANNE | Director | S-Sale | D | Common Stock | 500 | 476.12 | 238.1K | 4,700 | — | ↗ |
| 2023-05-05 | MCKEON BRIAN P | Officer | M-Exempt | D | Incentive Stock Option (right-to-buy) | 560 | 178.26 | 99.8K | 0 | — | ↗ |
| 2023-05-05 | Lane Michael | Officer | S-Sale | D | Common Stock | 1,000 | 484.00 | 484.0K | 4,022 | — | ↗ |
| 2023-05-05 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 2,500 | 0.00 | — | 143,019 | — | ↗ |
| 2023-05-04 | Vandebroek Sophie V. | Director | G-Gift | D | Common Stock | 500 | 0.00 | — | 8,173 | — | ↗ |
| 2023-05-04 | MAZELSKY JONATHAN JAY | Director / Officer | M-Exempt | A | Common Stock | 560 | 178.26 | 99.8K | 73,301 | — | ↗ |
| 2023-05-04 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 1 | 0.00 | — | 145,519 | — | ↗ |
| 2023-04-28 | JUNIUS DANIEL M | Director | A-Award | A | Common Stock | 13 | 492.16 | 6.4K | 2,995 | — | ↗ |
| 2023-02-16 | Turner Kathy V | Officer | S-Sale | D | Common Stock | 10 | 515.58 | 5.2K | 7,380 | — | ↗ |
| 2023-02-16 | JUNIUS DANIEL M | Director | M-Exempt | D | Non-Qualified Stock Option (right-to-buy) | 2,187 | 206.62 | 451.9K | 0 | — | ↗ |
| 2023-02-16 | AYERS JONATHAN W | Director | G-Gift | D | Common Stock | 1,000 | 0.00 | — | 145,520 | — | ↗ |
| 2023-02-15 | Turner Kathy V | Officer | A-Award | A | Common Stock | 1,000 | 79.54 | 79.5K | 8,380 | — | ↗ |
| 2023-02-14 | Underberg Sharon E. | Officer | M-Exempt | D | Restricted Stock Unit | 483 | 0.00 | — | 2,724 | — | ↗ |
| 2023-02-14 | Turner Kathy V | Officer | M-Exempt | A | Common Stock | 2,000 | 79.54 | 159.1K | 9,380 | — | ↗ |
| 2023-02-14 | Smith Martin Alexander | Officer | F-InKind | A | Common Stock | 47 | 503.65 | 23.7K | 180 | — | ↗ |
Executive team
Top executives
EBIT / Employee
123.9K
Shares Outstanding
79.62M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jonathan J. Mazelsky President and Chief Executive Officer | 1.15M | — | 5.40M | 5.40M | 2.59M | 37.2K | 14.58M | 74.07% | ↗ |
| 2 | 2025 | Michael J. Lane Executive Vice President and General Manager, CAG Diagnostics Business Unit | 594.1K | — | 1.35M | 1.35M | 627.3K | 98.3K | 4.02M | 67.17% | ↗ |
| 3 | 2025 | Tina Hunt, PhD Executive Vice President, Global Strategy and Commercial | 594.1K | — | 1.35M | 1.35M | 627.3K | 24.2K | 3.95M | 68.43% | ↗ |
| 4 | 2025 | Martin Smith, PhD Executive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security | 594.1K | — | 1.35M | 1.35M | 627.3K | 23.4K | 3.94M | 68.44% | ↗ |
| 5 | 2025 | Andrew Emerson Executive Vice President and Chief Financial Officer | 531.1K | — | 949.9K | 949.9K | 577.5K | 24.6K | 3.03M | 62.64% | ↗ |
| 6 | 2025 | Brian P. McKeon Former Executive Vice President, Chief Financial Officer and Treasurer | 293.4K | — | — | — | — | 58.3K | 351.7K | 0.00% | ↗ |
| 7 | 2024 | Jonathan J. Mazelsky President and Chief Executive Officer | 1.12M | — | 5.20M | 5.20M | 1.45M | 36.0K | 13.01M | 79.95% | ↗ |
| 8 | 2024 | Brian P. McKeon Former Executive Vice President, Chief Financial Officer and Treasurer | 689.6K | — | 1.34M | 1.34M | 504.5K | 23.8K | 3.89M | 68.72% | ↗ |
| 9 | 2024 | Brian P. McKeon Executive Vice President and Special Advisor (Former Chief Financial Officer and Treasurer) | 689.6K | — | 1.34M | 1.34M | 504.5K | 23.8K | 3.89M | 68.72% | ↗ |
| 10 | 2024 | Tina Hunt, PhD Executive Vice President, Global Strategy and Commercial | 576.6K | — | 1.35M | 1.35M | 422.0K | 32.3K | 3.73M | 72.37% | ↗ |
| 11 | 2024 | Michael J. Lane Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology | 576.6K | — | 1.35M | 1.35M | 422.0K | 27.9K | 3.73M | 72.45% | ↗ |
| 12 | 2024 | Michael J. Lane Executive Vice President and General Manager, CAG Diagnostics Business Unit | 576.6K | — | 1.35M | 1.35M | 422.0K | 27.9K | 3.73M | 72.45% | ↗ |
| 13 | 2024 | Martin Smith, PhD Executive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security | 576.6K | — | 1.35M | 1.35M | 422.0K | 20.7K | 3.72M | 72.59% | ↗ |
| 14 | 2024 | Martin Smith, PhD Executive Vice President, Global Operations and R&D | 576.6K | — | 1.35M | 1.35M | 422.0K | 20.7K | 3.72M | 72.59% | ↗ |
| 15 | 2023 | Jonathan J. Mazelsky President and Chief Executive Officer | 1.00M | — | 2.19M | 6.56M | 1.74M | 31.3K | 11.52M | 75.96% | ↗ |
| 16 | 2023 | Brian P. McKeon Former Executive Vice President, Chief Financial Officer and Treasurer | 669.0K | — | 612.3K | 1.84M | 701.6K | 24.5K | 3.85M | 63.72% | ↗ |
| 17 | 2023 | Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer | 669.0K | — | 612.3K | 1.84M | 701.6K | 24.5K | 3.85M | 63.72% | ↗ |
| 18 | 2023 | Brian P. McKeon Executive Vice President and Special Advisor (Former Chief Financial Officer and Treasurer) | 669.0K | — | 612.3K | 1.84M | 701.6K | 24.5K | 3.85M | 63.72% | ↗ |
| 19 | 2023 | Tina Hunt, PhD Executive Vice President, Global Strategy and Commercial | 559.2K | — | 1.16M | 1.24M | 586.4K | 25.3K | 3.57M | 67.21% | ↗ |
| 20 | 2023 | Tina Hunt, PhD Executive Vice President, Strategy, Sector Development and Global Operations | 559.2K | — | 1.16M | 1.24M | 586.4K | 25.3K | 3.57M | 67.21% | ↗ |
| 21 | 2023 | Michael J. Lane Executive Vice President and General Manager, Global Reference Laboratories and Information Technology | 559.2K | — | 437.7K | 1.31M | 586.4K | 25.5K | 2.92M | 59.91% | ↗ |
| 22 | 2023 | Michael J. Lane Executive Vice President and General Manager, CAG Diagnostics Business Unit | 559.2K | — | 437.7K | 1.31M | 586.4K | 25.5K | 2.92M | 59.91% | ↗ |
| 23 | 2023 | Michael J. Lane Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology | 559.2K | — | 437.7K | 1.31M | 586.4K | 25.5K | 2.92M | 59.91% | ↗ |
| 24 | 2023 | James F. Polewaczyk Executive Vice President and Chief Commercial Officer | 559.2K | — | 437.7K | 1.31M | 586.4K | 21.2K | 2.92M | 60.00% | ↗ |
| 25 | 2022 | Jonathan J. Mazelsky President and Chief Executive Officer | 1.00M | — | 1.94M | 5.81M | 1.01M | 25.6K | 9.79M | 79.18% | ↗ |
| 26 | 2022 | Brian P. McKeon Executive Vice President and Special Advisor (Former Chief Financial Officer and Treasurer) | 644.2K | — | 612.7K | 1.84M | 393.1K | 23.2K | 3.51M | 69.79% | ↗ |
| 27 | 2022 | Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer | 644.2K | — | 612.7K | 1.84M | 393.1K | 23.2K | 3.51M | 69.79% | ↗ |
| 28 | 2022 | Michael J. Lane Executive Vice President and General Manager, Global Reference Laboratories and Information Technology | 538.3K | — | 412.5K | 1.24M | 328.5K | 24.3K | 2.54M | 64.93% | ↗ |
| 29 | 2022 | Michael J. Lane Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology | 538.3K | — | 412.5K | 1.24M | 328.5K | 24.3K | 2.54M | 64.93% | ↗ |
| 30 | 2022 | James F. Polewaczyk Executive Vice President and Chief Commercial Officer | 538.3K | — | 412.5K | 1.24M | 328.5K | 23.2K | 2.54M | 64.96% | ↗ |
| 31 | 2022 | Tina Hunt, PhD Executive Vice President, Global Strategy and Commercial | 538.3K | — | 412.5K | 1.24M | 328.5K | 20.9K | 2.54M | 65.02% | ↗ |
| 32 | 2022 | Tina Hunt, PhD Executive Vice President, Strategy, Sector Development and Global Operations | 538.3K | — | 412.5K | 1.24M | 328.5K | 20.9K | 2.54M | 65.02% | ↗ |
| 33 | 2021 | Jonathan J. Mazelsky President and Chief Executive Officer | 976.9K | — | 1.50M | 4.50M | 2.06M | 26.3K | 9.07M | 66.18% | ↗ |
| 34 | 2021 | Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer | 625.5K | — | 550.1K | 1.65M | 777.5K | 22.2K | 3.63M | 60.68% | ↗ |
| 35 | 2021 | James F. Polewaczyk Executive Vice President and Chief Commercial Officer | 521.2K | — | 349.8K | 1.05M | 649.7K | 22.5K | 2.59M | 53.98% | ↗ |
| 36 | 2021 | Michael J. Lane Executive Vice President and General Manager, Global Reference Laboratories and Information Technology | 521.2K | — | 349.8K | 1.05M | 649.7K | 22.2K | 2.59M | 53.99% | ↗ |
| 37 | 2021 | Tina Hunt, PhD Executive Vice President, Strategy, Sector Development and Global Operations | 513.5K | — | 349.8K | 1.05M | 649.7K | 20.3K | 2.58M | 54.19% | ↗ |
| 38 | 2021 | Tina Hunt, PhD Executive Vice President, and General Manager, Point of Care Diagnostics and Worldwide Operations | 513.5K | — | 349.8K | 1.05M | 649.7K | 20.3K | 2.58M | 54.19% | ↗ |
| 39 | 2020 | Jonathan J. Mazelsky President and Chief Executive Officer | 814.0K | — | 1.13M | 3.38M | 1.70M | 24.0K | 7.04M | 63.94% | ↗ |
| 40 | 2020 | Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer | 597.2K | — | 499.9K | 1.50M | 732.0K | 21.1K | 3.35M | 59.70% | ↗ |
| 41 | 2020 | James F. Polewaczyk Executive Vice President and Chief Commercial Officer | 486.5K | — | 250.1K | 750.0K | 600.0K | 19.2K | 2.11M | 47.49% | ↗ |
| 42 | 2020 | Michael J. Lane Executive Vice President and General Manager, Reference Laboratories and IT | 485.5K | — | 200.1K | 600.0K | 600.0K | 23.3K | 1.91M | 41.91% | ↗ |
| 43 | 2020 | Michael J. Lane Executive Vice President and General Manager, Global Reference Laboratories and Information Technology | 485.5K | — | 200.1K | 600.0K | 600.0K | 23.3K | 1.91M | 41.91% | ↗ |
| 44 | 2020 | Sharon E. Underberg Senior Vice President, General Counsel and Corporate Secretary | 429.8K | — | 250.1K | 750.0K | 420.5K | 30.8K | 1.88M | 53.16% | ↗ |
| 45 | 2019 | Jonathan W. Ayers Former Board Chair, President and Chief Executive Officer | 692.3K | — | — | 5.00M | — | 2.50M | 8.19M | 61.04% | ↗ |
| 46 | 2019 | Jonathan J. Mazelsky President and Chief Executive Officer | 631.6K | — | 950.2K | 4.85M | 962.5K | 26.0K | 7.42M | 78.16% | ↗ |
| 47 | 2019 | Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer | 588.9K | — | 700.0K | 2.10M | 533.0K | 18.7K | 3.94M | 71.05% | ↗ |
| 48 | 2019 | Kathy V. Turner Corporate Vice President and Chief Marketing Officer | 409.7K | — | 187.5K | 562.4K | 296.6K | 1.24M | 2.70M | 27.81% | ↗ |
| 49 | 2019 | Sharon E. Underberg Corporate Vice President, General Counsel and Corporate Secretary | 359.6K | 112.0K | 500.0K | 499.8K | 272.3K | 65.5K | 1.81M | 55.26% | ↗ |
| 50 | 2019 | Sharon E. Underberg Senior Vice President, General Counsel and Corporate Secretary | 359.6K | 112.0K | 500.0K | 499.8K | 272.3K | 65.5K | 1.81M | 55.26% | ↗ |
| 51 | 2019 | Michael J. Lane Executive Vice President and General Manager, Reference Laboratories and Information Technology | 404.9K | — | 187.5K | 562.4K | 296.6K | 22.5K | 1.47M | 50.88% | ↗ |
| 52 | 2019 | Michael J. Lane Executive Vice President and General Manager, Reference Laboratories and IT | 404.9K | — | 187.5K | 562.4K | 296.6K | 22.5K | 1.47M | 50.88% | ↗ |
| 53 | 2019 | Michael J. Lane Executive Vice President and General Manager, Global Reference Laboratories and Information Technology | 404.9K | — | 187.5K | 562.4K | 296.6K | 22.5K | 1.47M | 50.88% | ↗ |
| 54 | 2018 | Jonathan W. Ayers Former Board Chair, President and Chief Executive Officer | 800.0K | — | — | 4.80M | 1.20M | 24.1K | 6.82M | 70.32% | ↗ |
| 55 | 2018 | Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer | 570.6K | — | 449.9K | 1.35M | 517.5K | 19.1K | 2.91M | 61.90% | ↗ |
| 56 | 2018 | Jonathan J. Mazelsky President and Chief Executive Officer | 555.4K | — | 449.9K | 1.35M | 517.5K | 25.4K | 2.90M | 62.09% | ↗ |
| 57 | 2018 | Kathy V. Turner Corporate Vice President and Chief Marketing Officer | 387.5K | — | 187.5K | 562.0K | 288.0K | 510.8K | 1.94M | 38.72% | ↗ |
| 58 | 2018 | Michael J. Lane Executive Vice President and General Manager, Reference Laboratories and Information Technology | 365.4K | — | 175.1K | 524.5K | 270.0K | 22.7K | 1.36M | 51.53% | ↗ |
| 59 | 2018 | Michael J. Lane Executive Vice President and General Manager, Reference Laboratories and IT | 365.4K | — | 175.1K | 524.5K | 270.0K | 22.7K | 1.36M | 51.53% | ↗ |
| 60 | 2018 | Kathy V. Turner Corporate Vice President | — | — | — | — | — | 510.8K | 510.8K | 0.00% | ↗ |
| 61 | 2018 | Jay Mazelsky Executive Vice President | — | — | — | — | — | 25.4K | 25.4K | 0.00% | ↗ |
| 62 | 2018 | Jonathan W. Ayers President and Chief Executive Officer | — | — | — | — | — | 24.1K | 24.1K | 0.00% | ↗ |
| 63 | 2018 | Michael J. Lane Corporate Vice President | — | — | — | — | — | 22.7K | 22.7K | 0.00% | ↗ |
| 64 | 2017 | Jonathan W. Ayers President and Chief Executive Officer | 800.0K | — | — | 4.49M | 1.35M | 22.2K | 6.67M | 67.41% | ↗ |
| 65 | 2017 | Jonathan W. Ayers Former Board Chair, President and Chief Executive Officer | 800.0K | — | — | 4.49M | 1.35M | 22.2K | 6.67M | 67.41% | ↗ |
| 66 | 2017 | Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer | 549.5K | — | 325.0K | 973.5K | 559.0K | 16.0K | 2.42M | 53.59% | ↗ |
| 67 | 2017 | Jay Mazelsky Executive Vice President | 469.5K | — | 325.0K | 973.5K | 479.0K | 22.9K | 2.27M | 57.21% | ↗ |
| 68 | 2017 | Jonathan J. Mazelsky President and Chief Executive Officer | 469.5K | — | 325.0K | 973.5K | 479.0K | 22.9K | 2.27M | 57.21% | ↗ |
| 69 | 2017 | Jacqueline L. Studer Corporate Vice President, General Counsel and Corporate Secretary | 385.2K | — | 150.0K | 449.3K | 313.0K | 22.6K | 1.32M | 45.40% | ↗ |
| 70 | 2017 | Giovani Twigge Corporate Vice President and Chief Human Resources Officer | 379.3K | — | 150.0K | 449.3K | 309.0K | 20.0K | 1.31M | 45.83% | ↗ |
| 71 | 2016 | Jonathan W. Ayers President and Chief Executive Officer | 800.0K | — | — | 3.50M | 1.55M | 20.8K | 5.86M | 59.65% | ↗ |
| 72 | 2016 | Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer | 533.5K | — | 275.0K | 824.5K | 621.0K | 17.2K | 2.27M | 48.41% | ↗ |
| 73 | 2016 | Jay Mazelsky Executive Vice President | 448.0K | — | 250.0K | 749.5K | 600.0K | 22.6K | 2.07M | 48.28% | ↗ |
| 74 | 2016 | Jacqueline L. Studer Corporate Vice President, General Counsel and Corporate Secretary | 373.3K | — | 137.5K | 412.2K | 324.0K | 36.1K | 1.28M | 42.84% | ↗ |
| 75 | 2016 | Giovani Twigge Corporate Vice President and Chief Human Resources Officer | 367.2K | — | 137.5K | 412.2K | 343.0K | 15.3K | 1.28M | 43.11% | ↗ |
| 76 | 2015 | Jonathan W. Ayers President and Chief Executive Officer | 800.0K | — | — | 3.00M | 950.0K | 20.8K | 4.77M | 62.86% | ↗ |
| 77 | 2015 | Jonathan W. Ayers President and Chief Executive Officer | 800.0K | — | — | 3.00M | 950.0K | 20.8K | 4.77M | 62.86% | ↗ |
| 78 | 2015 | Michael J. Williams, PhD Executive Vice President | 434.2K | — | 187.6K | 561.9K | 290.5K | 885.2K | 2.36M | 31.77% | ↗ |
| 79 | 2015 | Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer | 516.9K | — | 250.1K | 749.2K | 370.5K | 17.5K | 1.90M | 52.48% | ↗ |
| 80 | 2015 | Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer | 516.9K | — | 250.1K | 749.2K | 370.5K | 17.5K | 1.90M | 52.48% | ↗ |
| 81 | 2015 | Jay Mazelsky Executive Vice President | 434.2K | — | 187.6K | 561.9K | 290.5K | 23.2K | 1.50M | 50.05% | ↗ |
| 82 | 2015 | Jacqueline L. Studer Corporate Vice President, General Counsel and Corporate Secretary | 361.8K | — | 137.4K | 412.1K | 207.5K | 142.7K | 1.26M | 43.56% | ↗ |
| 83 | 2014 | Jonathan W. Ayers President and Chief Executive Officer | 800.0K | — | 549.9K | 1.65M | 1.31M | 16.7K | 4.33M | 50.83% | ↗ |
| 84 | 2014 | Jonathan W. Ayers President and Chief Executive Officer | 800.0K | — | 549.9K | 1.65M | 1.31M | 16.7K | 4.33M | 50.83% | ↗ |
| 85 | 2014 | Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer | 496.2K | — | 975.1K | 1.42M | 492.0K | 18.2K | 3.41M | 70.45% | ↗ |
| 86 | 2014 | Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer | 496.2K | — | 975.1K | 1.42M | 492.0K | 18.2K | 3.41M | 70.45% | ↗ |
| 87 | 2014 | Michael J. Williams, PhD Executive Vice President | 416.9K | — | 125.0K | 374.7K | 386.0K | 876.7K | 2.18M | 22.93% | ↗ |
| 88 | 2014 | Michael J. Williams, Ph.D. Executive Vice President | 416.9K | — | 125.0K | 374.7K | 386.0K | 876.7K | 2.18M | 22.93% | ↗ |
| 89 | 2014 | Jay Mazelsky Executive Vice President | 416.9K | — | 125.0K | 374.7K | 386.0K | 16.1K | 1.32M | 37.89% | ↗ |
| 90 | 2014 | Johnny D. Powers, Ph.D. Executive Vice President | 416.9K | — | 125.0K | 374.7K | 386.0K | 13.3K | 1.32M | 37.97% | ↗ |
| 91 | 2014 | Jacqueline L. Studer Corporate Vice President, General Counsel and Corporate Secretary | 181.7K | — | 350.0K | — | 161.0K | 67.0K | 759.7K | 46.07% | ↗ |
| 92 | 2013 | Jonathan W. Ayers President and Chief Executive Officer | 784.6K | — | 495.1K | 1.51M | 1.16M | 19.3K | 3.97M | 50.58% | ↗ |
| 93 | 2013 | Jonathan W. Ayers President and Chief Executive Officer | 784.6K | — | 495.1K | 1.51M | 1.16M | 19.3K | 3.97M | 50.58% | ↗ |
| 94 | 2013 | Jonathan W. Ayers President and Chief Executive Officer | 784.6K | — | 495.1K | 1.51M | 1.16M | 19.3K | 3.97M | 50.58% | ↗ |
| 95 | 2013 | Michael J. Williams, PhD Executive Vice President | 396.2K | — | 375.0K | 1.12M | 325.0K | 560.7K | 2.78M | 53.92% | ↗ |
| 96 | 2013 | Michael J. Williams, Ph.D. Executive Vice President | 396.2K | — | 375.0K | 1.12M | 325.0K | 560.7K | 2.78M | 53.92% | ↗ |
| 97 | 2013 | Michael J. Williams, Ph.D. Executive Vice President | 396.2K | — | 375.0K | 1.12M | 325.0K | 560.7K | 2.78M | 53.92% | ↗ |
| 98 | 2013 | Johnny D. Powers, Ph.D. Executive Vice President | 396.2K | — | 375.0K | 1.12M | 325.0K | 13.8K | 2.23M | 67.12% | ↗ |
| 99 | 2013 | Johnny D. Powers, Ph.D. Executive Vice President | 396.2K | — | 375.0K | 1.12M | 325.0K | 13.8K | 2.23M | 67.12% | ↗ |
| 100 | 2013 | Jay Mazelsky Executive Vice President | 396.2K | — | 375.0K | 1.12M | 325.0K | 11.8K | 2.23M | 67.17% | ↗ |
| 101 | 2013 | Jay Mazelsky Executive Vice President | 396.2K | — | 375.0K | 1.12M | 325.0K | 11.8K | 2.23M | 67.17% | ↗ |
| 102 | 2013 | Willard R. Blanche Jr. | 180.0K | 120.0K | 50.1K | 50.2K | — | 8.1K | 408.4K | 24.57% | ↗ |
| 103 | 2013 | Merilee Raines Former Executive Vice President and Chief Financial Officer | 132.4K | — | — | — | — | 22.5K | 154.9K | 0.00% | ↗ |
| 104 | 2013 | Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 105 | 2012 | Jonathan W. Ayers President and Chief Executive Officer | 700.0K | 1.00M | 524.5K | 1.58M | — | 18.4K | 3.82M | 55.07% | ↗ |
| 106 | 2012 | Jonathan W. Ayers President and Chief Executive Officer | 700.0K | 1.00M | 524.5K | 1.58M | — | 18.4K | 3.82M | 55.07% | ↗ |
| 107 | 2012 | Jay Mazelsky Executive Vice President | 155.8K | 350.0K | 562.5K | 187.5K | — | 77.7K | 1.33M | 56.24% | ↗ |
| 108 | 2012 | Jay Mazelsky Executive Vice President | 155.8K | 350.0K | 562.5K | 187.5K | — | 77.7K | 1.33M | 56.24% | ↗ |
| 109 | 2012 | Michael J. Williams, Ph.D. Executive Vice President | 358.7K | 300.0K | 112.5K | 337.5K | — | 25.9K | 1.13M | 39.66% | ↗ |
| 110 | 2012 | Michael J. Williams, PhD Executive Vice President | 358.7K | 300.0K | 112.5K | 337.5K | — | 25.9K | 1.13M | 39.66% | ↗ |
| 111 | 2012 | Michael J. Williams, Ph.D. Executive Vice President | 358.7K | 300.0K | 112.5K | 337.5K | — | 25.9K | 1.13M | 39.66% | ↗ |
| 112 | 2012 | Johnny D. Powers, PhD Executive Vice President | 359.4K | 300.0K | 112.5K | 337.5K | — | 13.0K | 1.12M | 40.09% | ↗ |
| 113 | 2012 | Johnny D. Powers, Ph.D. Executive Vice President | 359.4K | 300.0K | 112.5K | 337.5K | — | 13.0K | 1.12M | 40.09% | ↗ |
| 114 | 2012 | Johnny D. Powers, Ph.D. Executive Vice President | 359.4K | 300.0K | 112.5K | 337.5K | — | 13.0K | 1.12M | 40.09% | ↗ |
| 115 | 2012 | Merilee Raines Former Executive Vice President and Chief Financial Officer | 350.2K | 246.4K | 118.7K | 356.2K | — | 15.5K | 1.09M | 43.69% | ↗ |
| 116 | 2012 | Merilee Raines Executive Vice President and Chief Financial Officer | 350.2K | 246.4K | 118.7K | 356.2K | — | 15.5K | 1.09M | 43.69% | ↗ |
| 117 | 2012 | Brian P. McKeon Executive Vice President, Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 118 | 2011 | Jonathan W. Ayers President and Chief Executive Officer | 700.0K | 1.00M | 465.5K | 6.50M | — | 17.1K | 8.68M | 80.22% | ↗ |
| 119 | 2011 | Michael J. Williams, Ph.D. Executive Vice President | 319.6K | 300.0K | 600.0K | 800.1K | — | 10.2K | 2.03M | 68.97% | ↗ |
| 120 | 2011 | Michael J. Williams, PhD Executive Vice President | 319.6K | 300.0K | 600.0K | 800.1K | — | 10.2K | 2.03M | 68.97% | ↗ |
| 121 | 2011 | Michael J. Williams, PhD Corporate Vice President, Instrument Diagnostics | 319.6K | 300.0K | 600.0K | 800.1K | — | 10.2K | 2.03M | 68.97% | ↗ |
| 122 | 2011 | Johnny D. Powers, Ph.D. Executive Vice President | 326.5K | 300.0K | 593.7K | 781.3K | — | 10.5K | 2.01M | 68.34% | ↗ |
| 123 | 2011 | Johnny D. Powers, PhD Executive Vice President | 326.5K | 300.0K | 593.7K | 781.3K | — | 10.5K | 2.01M | 68.34% | ↗ |
| 124 | 2011 | Johnny D. Powers, PhD Corporate Vice President, IDEXX Reference | 326.5K | 300.0K | 593.7K | 781.3K | — | 10.5K | 2.01M | 68.34% | ↗ |
| 125 | 2011 | Merilee Raines Executive Vice President and Chief Financial Officer | 336.6K | 275.0K | 118.7K | 356.2K | — | 10.7K | 1.10M | 43.29% | ↗ |
| 126 | 2011 | Merilee Raines Former Executive Vice President and Chief Financial Officer | 336.6K | 275.0K | 118.7K | 356.2K | — | 10.7K | 1.10M | 43.29% | ↗ |
| 127 | 2011 | Merilee Raines Corporate Vice President and Chief Financial Officer | 336.6K | 275.0K | 118.7K | 356.2K | — | 10.7K | 1.10M | 43.29% | ↗ |
| 128 | 2011 | William E. Brown III, PhD Corporate Vice President and | 322.3K | 250.0K | 106.2K | 318.7K | — | 10.9K | 1.01M | 42.15% | ↗ |
| 129 | 2010 | Jonathan W. Ayers President and Chief Executive Officer | 700.0K | 900.0K | 426.5K | 1.32M | — | 16.0K | 3.36M | 51.97% | ↗ |
| 130 | 2010 | William E. Brown III, PhD | 306.3K | 250.0K | 112.5K | — | — | 49.3K | 1.05M | 10.68% | ↗ |
| 131 | 2010 | William E. Brown III, PhD Corporate Vice President and | 306.3K | 250.0K | 112.5K | 335.5K | — | 49.3K | 1.05M | 42.52% | ↗ |
| 132 | 2010 | Merilee Raines Corporate Vice President and Chief Financial Officer | 316.6K | 270.0K | 112.5K | 335.5K | — | 10.6K | 1.05M | 42.87% | ↗ |
| 133 | 2010 | Merilee Raines Executive Vice President and Chief Financial Officer | 316.6K | 270.0K | 112.5K | 335.5K | — | 10.6K | 1.05M | 42.87% | ↗ |
| 134 | 2010 | Johnny D. Powers, PhD Corporate Vice President, IDEXX Reference | 306.3K | 250.0K | 100.0K | 298.3K | — | 13.7K | 968.3K | 41.13% | ↗ |
| 135 | 2010 | Johnny D. Powers, PhD Executive Vice President | 306.3K | 250.0K | 100.0K | — | — | 13.7K | 968.3K | 10.33% | ↗ |
| 136 | 2010 | Michael J. Williams, PhD Corporate Vice President, Instrument Diagnostics | 286.2K | 240.0K | 106.2K | 316.9K | — | 10.1K | 959.4K | 44.10% | ↗ |
| 137 | 2010 | Michael J. Williams, PhD Executive Vice President | 286.2K | 240.0K | 106.2K | — | — | 10.1K | 959.4K | 11.07% | ↗ |
| 138 | 2009 | Jonathan W. Ayers President and Chief Executive Officer | 726.9K | 825.0K | 275.0K | 801.8K | — | 13.7K | 2.64M | 40.75% | ↗ |
| 139 | 2009 | Merilee Raines Corporate Vice President and Chief Financial Officer | 321.9K | 240.0K | 75.0K | 226.9K | — | 10.6K | 874.4K | 34.52% | ↗ |
| 140 | 2009 | Johnny D. Powers, PhD Corporate Vice President, IDEXX Reference | 270.0K | 200.0K | 87.5K | 264.7K | — | 49.0K | 871.2K | 40.43% | ↗ |
| 141 | 2009 | Michael J. Williams, PhD Corporate Vice President, Instrument Diagnostics | 275.0K | 200.0K | 68.7K | 208.0K | — | 9.3K | 761.0K | 36.36% | ↗ |
| 142 | 2009 | Thomas J. Dupree Corporate Vice President, Companion Animal Group | 275.0K | 210.0K | — | — | — | — | 485.0K | 0.00% | ↗ |
| 143 | 2009 | Michael J. Williams, PhD Corporate Vice President, Instrument Diagnostics | 275.0K | 200.0K | — | — | — | — | 475.0K | 0.00% | ↗ |
| 144 | 2009 | Johnny D. Powers, PhD Corporate Vice President, IDEXX Reference | 270.0K | 200.0K | — | — | — | — | 470.0K | 0.00% | ↗ |
| 145 | 2008 | Jonathan W. Ayers President and Chief Executive Officer | 700.0K | 675.0K | 341.7K | — | — | 13.1K | 2.65M | 12.90% | ↗ |
| 146 | 2008 | Merilee Raines Corporate Vice President and Chief Financial Officer | 310.0K | 200.0K | 110.0K | — | — | 10.1K | 969.5K | 11.35% | ↗ |
| 147 | 2008 | William C. Wallen, PhD Senior Vice President and Chief Scientific Officer | 375.0K | 200.0K | 28.7K | — | — | 11.8K | 830.8K | 3.45% | ↗ |
| 148 | 2008 | Conan R. Deady Corporate Vice President, General Counsel Secretary | 280.0K | 160.0K | 42.6K | — | — | 10.0K | 673.4K | 6.33% | ↗ |
| 149 | 2008 | Thomas J. Dupree Corporate Vice President, | 260.0K | 155.0K | 47.4K | — | — | 8.1K | 623.5K | 7.61% | ↗ |
| 150 | 2008 | Thomas J. Dupree Corporate Vice President, Companion Animal Group | 260.0K | 155.0K | — | — | — | — | 415.0K | 0.00% | ↗ |
| 151 | 2007 | Jonathan W. Ayers President and Chief | 650.0K | 650.0K | 82.5K | — | — | 13.8K | 2.57M | 3.21% | ↗ |
| 152 | 2007 | Jonathan W. Ayers President and Chief Executive Officer | 650.0K | 650.0K | — | — | — | — | 1.30M | 0.00% | ↗ |
| 153 | 2007 | William C. Wallen, PhD Senior Vice President | 365.0K | 275.0K | 17.5K | — | — | 10.5K | 1.01M | 1.73% | ↗ |
| 154 | 2007 | William C. Wallen, PhD Senior Vice President and Chief Scientific Officer | 365.0K | 275.0K | 17.5K | — | — | 10.5K | 1.01M | 1.73% | ↗ |
| 155 | 2007 | Merilee Raines Corporate Vice President | 290.0K | 225.0K | 27.0K | — | — | 2.0K | 755.0K | 3.58% | ↗ |
| 156 | 2007 | Conan R. Deady Corporate Vice President | 260.0K | 180.0K | 25.2K | — | — | 8.7K | 655.9K | 3.84% | ↗ |
| 157 | 2007 | Conan R. Deady Corporate Vice President, General Counsel Secretary | 260.0K | 180.0K | 25.2K | — | — | 8.7K | 655.9K | 3.84% | ↗ |
| 158 | 2007 | Thomas J. Dupree Corporate Vice President, Companion Animal Group | 225.0K | 185.0K | 27.8K | — | — | 6.8K | 572.3K | 4.85% | ↗ |
| 159 | 2007 | Merilee Raines Corporate Vice President and Chief Financial Officer | 290.0K | 225.0K | — | — | — | — | 515.0K | 0.00% | ↗ |
| 160 | 2007 | Thomas J. Dupree Corporate Vice President, Companion Animal Group | 225.0K | 185.0K | — | — | — | — | 410.0K | 0.00% | ↗ |
| 161 | 2006 | Jonathan W. Ayers President and Chief Executive Officer | 600.0K | 650.0K | 33.6K | — | — | 16.3K | 2.46M | 1.37% | ↗ |
| 162 | 2006 | Jonathan W. Ayers President and Chief | 600.0K | 650.0K | 33.6K | — | — | 16.3K | 2.46M | 1.37% | ↗ |
| 163 | 2006 | Jonathan W. Ayers President and Chief Executive Officer | 600.0K | 650.0K | 33.6K | 1.16M | — | 16.3K | 2.46M | 48.42% | ↗ |
| 164 | 2006 | William C. Wallen, PhD Senior Vice President | 350.0K | 255.0K | 6.7K | — | — | 11.9K | 1.13M | 0.59% | ↗ |
| 165 | 2006 | William C. Wallen, PhD Senior Vice President and Chief Scientific Officer | 350.0K | 255.0K | 6.7K | — | — | 11.9K | 1.13M | 0.59% | ↗ |
| 166 | 2006 | William C. Wallen, PhD Senior Vice President Chief Scientific Officer | 350.0K | 255.0K | 6.7K | 506.8K | — | 11.9K | 1.13M | 45.43% | ↗ |
| 167 | 2006 | Robert S. Hulsy Corporate Vice President IDEXX Reference Laboratories and Digital | 260.0K | 200.0K | 8.3K | 235.8K | — | — | 704.1K | 34.67% | ↗ |
| 168 | 2006 | Merilee Raines Corporate Vice President | 260.0K | 200.0K | 8.3K | — | — | 2.0K | 702.1K | 1.18% | ↗ |
| 169 | 2006 | Merilee Raines Corporate Vice President and Chief Financial Officer | 260.0K | 200.0K | 8.3K | 231.8K | — | 2.0K | 702.1K | 34.20% | ↗ |
| 170 | 2006 | Merilee Raines Corporate Vice President and Chief Financial Officer | 260.0K | 200.0K | 8.3K | — | — | 2.0K | 702.1K | 1.18% | ↗ |
| 171 | 2006 | Conan R. Deady Corporate Vice President, General Counsel Secretary | 230.0K | 175.0K | 6.7K | 198.8K | — | 8.6K | 619.0K | 33.19% | ↗ |
| 172 | 2006 | Conan R. Deady Corporate Vice President, General Counsel Secretary | 230.0K | 175.0K | 6.7K | — | — | 8.6K | 619.0K | 1.08% | ↗ |
| 173 | 2006 | Conan R. Deady Corporate Vice President | 230.0K | 175.0K | 6.7K | — | — | 8.6K | 619.0K | 1.08% | ↗ |
| 174 | 2001 | David E. Shaw President and Chief Executive | 500.0K | 280.0K | — | — | — | 5.3K | 785.3K | 0.00% | ↗ |
| 175 | 2001 | Erwin F. Workman, Jr., Ph.D Executive Vice President and | 305.1K | 134.4K | — | — | — | 5.3K | 444.8K | 0.00% | ↗ |
| 176 | 2001 | Louis W. Pollock Senior Vice President | 260.0K | 76.4K | — | — | — | 5.3K | 341.7K | 0.00% | ↗ |
| 177 | 2001 | Robert S. Hulsy Vice President | 200.0K | 84.0K | — | — | — | — | 284.0K | 0.00% | ↗ |
| 178 | 2001 | Merilee Raines Vice President | 185.0K | 77.7K | — | — | — | — | 262.7K | 0.00% | ↗ |
| 179 | 2000 | David E. Shaw Officer | 467.0K | 382.5K | — | — | — | 5.1K | 854.6K | 0.00% | ↗ |
| 180 | 2000 | David E. Shaw President and Chief Executive | 467.0K | 382.5K | — | — | — | 5.1K | 854.6K | 0.00% | ↗ |
| 181 | 2000 | Erwin F. Workman, Jr., Ph.D Executive Vice President and | 302.5K | 194.4K | — | — | — | 5.1K | 502.0K | 0.00% | ↗ |
| 182 | 2000 | Erwin F. Workman, Jr., Ph.D. Chief Scientific Officer | 302.5K | 194.4K | — | — | — | 5.1K | 502.0K | 0.00% | ↗ |
| 183 | 2000 | Louis W. Pollock Senior Vice President | 227.5K | 132.0K | — | — | — | 5.1K | 364.6K | 0.00% | ↗ |
| 184 | 2000 | Louis W. Pollock Senior Vice President | 227.5K | 132.0K | — | — | — | 5.1K | 364.6K | 0.00% | ↗ |
| 185 | 2000 | Salvator S. Fratoni, Ph.D. | 180.1K | 92.3K | — | — | — | 5.1K | 277.5K | 0.00% | ↗ |
| 186 | 2000 | Roland H. Johnson | 215.0K | 56.9K | — | — | — | 5.1K | 277.0K | 0.00% | ↗ |
| 187 | 2000 | Merilee Raines Vice President | 180.0K | 90.8K | — | — | — | — | 270.8K | 0.00% | ↗ |
| 188 | 2000 | Robert S. Hulsy Vice President | 177.6K | 92.3K | — | — | — | — | 269.9K | 0.00% | ↗ |
| 189 | 2000 | Ralph K. Carlton | 250.8K | — | — | — | — | — | 250.8K | 0.00% | ↗ |
| 190 | 1999 | David E. Shaw Officer | 386.0K | 320.0K | — | — | — | 4.8K | 710.8K | 0.00% | ↗ |
| 191 | 1999 | David E. Shaw President and Chief Executive | 386.0K | 320.0K | — | — | — | 4.8K | 710.8K | 0.00% | ↗ |
| 192 | 1999 | Erwin F. Workman, Jr., Ph.D. Chief Scientific Officer | 296.5K | 188.8K | — | — | — | 4.8K | 490.1K | 0.00% | ↗ |
| 193 | 1999 | Erwin F. Workman, Jr., Ph.D Executive Vice President and | 296.5K | 188.8K | — | — | — | 4.8K | 490.1K | 0.00% | ↗ |
| 194 | 1999 | Ralph K. Carlton | 260.0K | 134.3K | — | — | — | — | 394.3K | 0.00% | ↗ |
| 195 | 1999 | Roland H. Johnson | 215.9K | 83.3K | — | — | — | 5.0K | 304.2K | 0.00% | ↗ |
| 196 | 1999 | Louis W. Pollock Senior Vice President | 188.5K | 109.4K | — | — | — | 4.8K | 302.7K | 0.00% | ↗ |
| 197 | 1999 | Louis W. Pollock Senior Vice President | 188.5K | 109.4K | — | — | — | 4.8K | 302.7K | 0.00% | ↗ |
| 198 | 1999 | Salvator S. Fratoni, Ph.D. | 180.0K | 79.7K | — | — | — | 4.8K | 264.5K | 0.00% | ↗ |
| 199 | 1999 | Robert S. Hulsy Vice President | 170.1K | 84.3K | — | — | — | — | 254.4K | 0.00% | ↗ |
| 200 | 1999 | Merilee Raines Vice President | 150.2K | 72.0K | — | — | — | — | 222.2K | 0.00% | ↗ |
| 201 | 1998 | David E. Shaw Officer | 439.5K | 378.0K | — | — | — | 3.4K | 820.9K | 0.00% | ↗ |
| 202 | 1998 | Erwin F. Workman, Jr., Ph.D. Chief Scientific Officer | 306.7K | 216.0K | — | — | — | 3.2K | 525.9K | 0.00% | ↗ |
| 203 | 1998 | Ralph K. Carlton | 269.4K | 147.0K | — | — | — | — | 416.4K | 0.00% | ↗ |
| 204 | 1998 | Louis W. Pollock Senior Vice President | 186.4K | 92.0K | — | — | — | 3.2K | 281.6K | 0.00% | ↗ |
| 205 | 1998 | Salvator S. Fratoni, Ph.D. | 185.8K | 85.0K | — | — | — | 3.2K | 274.0K | 0.00% | ↗ |
| 206 | 1998 | Roland H. Johnson | 51.6K | 206.0K | — | — | — | — | 257.6K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jonathan J. Mazelsky | President, Chief Executive Officer & Director | 4M | male |
| Michael J. Lane | Executive Vice President and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology | 1M | male |
| Nimrata Khatra Hunt | Advisor | 1M | — |
| Martin Smith | Executive Vice President of Global Operations and R&D | 1M | — |
| Andrew Emerson | Executive Vice President, Chief Financial Officer & Treasurer | 1M | male |
| Sharon E. Underberg | Executive Vice President, General Counsel, & Corporate Secretary | 881.1K | female |
| Julie Godon | Senior Vice President & Global Marketing Officer | — | female |
| Jeffery D. Chadbourne | Senior Vice President of Commercial Finance & Sales Operations | — | male |
| Michael Erickson | Executive Vice President and GM of Point of Care Diagnostics & Telemedicine | — | male |
| George J. Fennell | Executive Vice President of Global CAG Commercial | — | male |
| Michael Johnson | Executive Vice President & Chief Human Resources Officer | — | male |
| Murthy Yerramilli | Senior VP of Assay and Instrument Research & Development | — | male |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2024-01-22 | 2024-02-14 | Tommy Tuberville | AL | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2023-04-03 | 2023-05-11 | Tommy Tuberville | AL | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2022-10-05 | 2022-11-10 | Tommy Tuberville | AL | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2021-03-29 | 2021-07-23 | Tommy Tuberville | AL | Joint | Purchase | $1,001 - $15,000 | ↗ |
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-01-13 | 2026-02-03 | April Delaney | MD06 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-12-02 | 2026-01-06 | April Delaney | MD06 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-10-29 | 2025-11-05 | April Delaney | MD06 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-10-16 | 2025-11-05 | April Delaney | MD06 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-09-05 | 2025-10-03 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-09-04 | 2025-10-08 | Byron Donalds | FL19 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-08-07 | 2025-09-03 | April Delaney | MD06 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-08-01 | 2025-09-03 | April Delaney | MD06 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-07-09 | 2025-08-06 | April Delaney | MD06 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-05-15 | 2025-06-10 | Rob Bresnahan | PA08 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-09 | 2025-05-02 | April Delaney | MD06 | Dependent | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-08 | 2025-04-29 | Rob Bresnahan | PA08 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-04-07 | 2025-05-09 | Jefferson Shreve | IN06 | — | Purchase | $50,001 - $100,000 | ↗ |
| 2025-04-07 | 2025-05-02 | April Delaney | MD06 | Dependent | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-04 | 2025-05-02 | April Delaney | MD06 | Dependent | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-01 | 2025-05-02 | April Delaney | MD06 | Dependent | Purchase | $1,001 - $15,000 | ↗ |
| 2025-03-14 | 2025-04-03 | April Delaney | MD06 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-03-13 | 2025-04-14 | Jefferson Shreve | IN06 | — | Purchase | $15,001 - $50,000 | ↗ |
| 2025-02-25 | 2025-03-28 | Rob Bresnahan | PA08 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2024-03-25 | 2024-04-05 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IDXX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
